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resumo 
 
 
O nosso cérebro é uma estrutura complexa constituída por neurónios capazes 
de comunicar entre si através de sinapses, que geralmente ocorrem entre o 
terminal axonal e a espinha dendrítica de dois neurónios. Estas espinhas 
dendríticas são dinâmicas, permitindo assim que se adaptem aos estímulos 
que recebem, quer estimulantes quer inibitórios. A PP1 é uma proteína 
fosfatase que catalisa grande parte das reações de desfosforilação que 
ocorrem no nosso corpo, encontrando-se envolvida, por isso, em diversas 
funções, desde o metabolismo do glicogénio até à regulação sináptica. As 
neurabinas são duas proteínas estrutural e funcionalmente similares, muito 
concentradas nas espinhas dendríticas, onde interagem com diversas 
proteínas, incluindo a PP1, e as direcionam ou para os recetores que aqui se 
encontram, ou para o citoesqueleto de actina ou para outras regiões do 
neurónio. Assim, as neurabinas são responsáveis pela regulação da 
morfologia neuronal, pela transmissão sináptica e, por conseguinte, pela 
plasticidade sináptica. A doença de Alzheimer é a doença neurodegenerativa 
mais comum e é caraterizada por depósitos de Aβ e presença de tranças 
neurofibrilares, pela destruição de sinapses e morte neuronal, e pela perda 
gradual da memória e de outras funções cognitivas. A PPA é uma proteína 
transmembranar que, na doença de Alzheimer, é processada anormalmente 
pela via amiloidogénica, resultando na sobreprodução de Aβ, um peptídeo 
tóxico, que se crê ser o principal causador das alterações caraterísticas da 
doença de Alzheimer. 
O principal objetivo desta tese de mestrado foi avaliar o efeito do Aβ na 
expressão das neurabinas e na interação destas com a PP1. Os resultados 
aqui reportados demonstram uma ligeira diminuição de ambas as neurabinas 
quando o Aβ se encontra presente nas células, provavelmente pelas 
alterações a nível morfológico e destruição de sinapses que ocorre. Também 
foi aqui reportado que o Aβ interfere com o complexo neurabina-1/PP1, talvez 
pelo efeito direto do Aβ na neurabina-1 ou pela desregulação de fosfatases e 
cinases existente quando o Aβ se encontra presente no meio, levando a uma 
diminuição da afinidade entre a neurabina-1 e a PP1. O mesmo efeito não se 
verificou no complexo neurabina-2/PP1, talvez por serem reguladas de forma 
diferente por diferentes cinases. O estudo imunocitoquímico não demonstrou 
alterações a nível da co-localização entre a neurabina-1 e a PP1, e permitiu a 
caraterização da distribuição celular de ambas as neurabinas em células SH-
SY5Y. 
As experiências laboratoriais realizadas nesta tese permitiram concluir que o 
Aβ interfere com a expressão das neurabinas e com o complexo neurabina-
1/PP1. No entanto, terão que ser realizados estudos adicionais para 
compreender a relevância fisiológica do complexo neurabina-1/PP1. 
 
  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Aβ, Alzheimer’s disease, neurabin-1, neurabin-2, PP1, interaction, SH-SY5Y 
cells, differentiation, co-localization 
 
abstract 
 
Our brain is a complex structure constituted by neurons capable of 
communicating through synapses, which generally occur between the axon 
terminal and the dendritic spine of two different neurons. These dendritic spines 
are dynamic, which allow for the rapid adaptation to the different stimuli they 
receive. PP1 is a phosphatase protein which catalyzes the majority of 
dephosphorylation reactions that occur in our body. It is involved in several 
different functions, from glycogen metabolism to synaptic regulation. Neurabins 
are two structurally and functionally similar proteins, highly concentrated in 
dendritic spines, where they interact with several proteins – PP1 included –, 
and target them to receptors, the cytoskeleton and to other cellular 
compartments. Thus, neurabins regulate neuronal morphology and synaptic 
transmission, and hence, synaptic plasticity. Alzheimer’s disease is the most 
common neurodegenerative disease and it is characterized by the deposition of 
Aβ and the presence of neurofibrilliary tangles, by the loss of synapses and 
neuronal death, and by the gradual loss of memory and other cognitive 
functions. APP is an integral membrane protein which, in Alzheimer’s disease, 
is abnormally cleaved via the amyloidogenic pathway, thus resulting in the 
overproduction of a toxic peptide, Aβ, believed to be the major culprit of the 
changes observed in this disease. 
The main aim of this thesis was to study the effects of Aβ on neurabins 
expression and to evaluate its effects on the neurabin/PP1 complex. The 
results here reported showed a slight decrease in both neurabins expression  
levels when Aβ was added to the cells, possibly due to the morphological 
changes and synaptic dysfunction this peptide induces. It was also here 
reported that Aβ interferes with the neurabin-1/PP1 complex. This may be 
related to the direct effect of Aβ on neurabin-1 or due to the imbalance of 
phosphatases and kinases seen when Aβ is added, which could result in a 
decrease of neurabin-1’s affinity for PP1. The same effect was not seen with 
the neurabin-2/PP1 complex, possibly because they are differently regulated by 
several kinases. The immunocytochemistry study here performed did not show 
any changes between the co-localization of neurabin-1 and PP1, and allowed 
for assessment of cellular distribution of neurabin-1 and neurabin-2 in SH-
SY5Y cells. 
The experimental procedures here performed allowed us to conclude that Aβ 
interferes with the expression of both neurabins and with the interaction 
between neurabin-1 and PP1. However, additional studies need to be 
conducted in order to understand the physiological relevance of this complex. 
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1. Introduction
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The human brain. A highly complex structure that governs our lives. Within it lies 
everything we do, think and feel. It dictates how we react in front of our family, our loved ones, 
and even in front of a perilous situation. It is the command center of all our actions, thoughts, 
memories and emotions. Such complex structure needs a highly organized interconnected network 
to guarantee that its functions are properly executed. 
This network is constituted by neurons (and also supporting glial cells) capable of 
communicating with each other through synapses, especially chemical synapses. Chemical 
synapses rely on the transfer of endogenous chemical compounds – neurotransmitters – between a 
pre- and a postsynaptic neuron. These neurotransmitters are produced on the presynaptic neuron 
and wrapped in membrane-bounded organelles – synaptic vesicles -, which are then secreted to the 
synaptic cleft. After diffusing across the synaptic cleft, neurotransmitters bind to specific receptors 
present on the membrane of the postsynaptic neuron 
1
 (Figure 1). 
 
Figure 1 – Chemical synapse. An action potential invades the presynaptic terminal (A) and there is 
the production of neurotransmitters (1). A synaptic vesicle is formed (2), wraps the newly-formed 
neurotransmitters (3), which are then released into the synaptic cleft (4). Here they bind to receptors (5) and 
then cause an excitatory or inhibitory potential that changes the excitability of the postsynaptic neuron (6). A, 
presynaptic neuron; B, postsynaptic neuron; C, synaptic cleft (adapted from 
1
). 
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1.1. Dendritic spines 
The type of neuronal communication, mentioned above, usually occurs between an axon 
terminal (presynaptic component) and dendritic spines (postsynaptic component). Dendritic spines 
are membranous protrusions composed of a spine head and a spine neck which arise from the 
dendritic shaft 
2,3
. These dendritic spines are present on different populations of neurons in the 
brain and are preferentially located on the peripheral dendrites of neocortical and hippocampal 
pyramidal neurons, on the striatum and in cerebellar Purkinje cells 
2,4
. They are thought to be key 
structures in both learning and memory formation, as they receive the majority of excitatory and 
inhibitory outputs in the central nervous system 
2,5
.   
1.1.1. Structure and Composition 
Dendritic spines can be classified in three major types: thin (“thin spines”), short without a 
well-defined spine deck (“stubby spines”) or with a large bulbous head (“mushroom spines”) 2–4,6 
(Figure 2). However, dendritic spines are not static, i.e., they do not always have the same 
structure, since in developing neurons, the majority of dendritic spines change their shape over 
periods of minutes or hours. As for dendritic spines in mature neurons, they are not as motile as in 
developing neurons and thus, there are fewer changes in their shape. Larger spines (mushroom 
spines, for example) are functionally stronger in their response to glutamate, regulation of 
intracellular calcium, protein translation and degradation, and endosomal recycling than smaller 
spines, which are more flexible, rapidly enlarging or shrinking in response to subsequent activation 
6,7
. 
 
Figure 2 – Dendritic spine morphology. It is possible to distinguish several types of dendritic spines 
(yellow). Arrow, arrowhead and asterisk, represent thin, stubby and mushroom spines, respectively (adapted 
from 
6
). 
The first structure of the dendritic spine, and probably the most complex spine organelle, is 
the postsynaptic density (PSD), an electron-dense thickening of the postsynaptic membrane that 
harbors hundreds of proteins involved in synaptic plasticity, including neurotransmitter receptors, 
such as N-methyl-ᴅ-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole 
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propionic acid (AMPA) receptors, kainaite and metabotropic glutamate receptors, along with 
numerous signaling and scaffolding proteins 
2,4,7,8
. 
Below the PSD we can find both monomeric (globular, G-actin) and filamentous (F-actin) 
actin. The spines’ cytoskeleton is rich in F-actin, which modulates spine head structure in response 
to postsynaptic signaling and contributes to the overall structure of synapses. It organizes the PSD, 
anchoring and stabilizing postsynaptic receptors and localizing the translation machinery. The 
dendritic spine is rich in actin-binding proteins, actin-associated proteins and some small GTPases 
that cooperate to regulate actin-based cellular events, such as the formation, elimination, motility, 
stability, size and shape of dendritic spines 
2,6
. This actin cytoskeleton helps explain why a variety 
of dendritic spines exist, since actin is very dynamic and allows for changes in size and shape of 
dendritic spines 
2
. 
Additionally, several other organelles can be found within dendritic spines, such as the 
smooth endoplasmic reticulum, a spine apparatus, clusters of polyribosomes and proteasomes 
2,7
. 
1.1.2. Dendritic spine formation 
There are three main views on the origin of dendritic spines which imply different molecular 
mechanisms of spine origin. The first model states that once dendritic filopodia predominant in 
younger neurons establish synaptic contact they originate dendritic spines. This model is based on 
the fact that, as synapses form, the number of filopodia declines and the number of spine-like 
structures increases, which may suggest that filopodia are the precursors of dendritic spines. So, 
this model suggests that the highly motile filopodia act as a “probing unit” that searches for 
appropriate contacts 
4
. The axon guidance (suggested by the fact that release of glutamate from 
sites of presynaptic vesicle release promotes filopodia extension) and cell adhesion molecules 
present on developing dendrites and axons may contribute to directing the movements of filopodia 
and their selective adhesion to a compatible axonal partner 
4,9
. 
The second model proposes that dendritic spines arise from synapses that are initially formed 
on the dendritic shaft. This view is supported from the observation that the majority of synapses in 
younger pyramidal neurons are located on the dendritic shaft rather than on filopodia 
4,10
. 
The third model states that spines can form even without synaptic contact. Spines of the 
distal dendritic branches of cerebellar Purkinje neurons form before the establishment of synaptic 
contact with the presynaptic parallel fibers 
4,10
. 
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Since these three models base their assumptions on different types of neurons, it is more 
likely that dendritic spines emerge through different mechanisms depending on the type of neuron 
4
. However, it has also been proposed that these three models might be part of the same process, 
which occur in specific temporal periods of a neuron’s life and may be dependent on the maturation 
of its dendritic structures (filopodia and dendritic spines) 
10
. 
Following genesis of dendritic spines, they pass through a process of maturation where there 
is an increase in spine density, a decrease in overall length and a decrease in the number of 
dendritic filopodia with a simultaneous decrease in spine motility 
7
. This maturation process also 
results in synapse maturation which involves the further recruitment of presynaptic and 
postsynaptic components (scaffolding proteins and neurotransmitters receptors, for example) 
11
. 
Finally, after maturation of dendritic spines and formed synapses, there is a retraction of 
some contacts and elimination of inappropriate synaptic proteins, which refine the neuronal 
circuitry 
9
, together with long-term potentiation (LTP) and long term depression (LTD) (Figure 3) 
11
. 
 
Figure 3 – Dendritic spines development. In the early stages, filopodia begin to differentiate into 
more mature dendritic spines, which then are refined through LTP or LTD, causing an enlargement or 
shrinking of the spines, respectively (adapted from 
7
). 
1.1.3. Dendritic spines and synaptic plasticity 
Synaptic plasticity is the ability that neurons have to positively or negatively change the 
efficacy of their connections in response to neuronal activity 
1,2
. This synaptic connectivity is a 
dynamic entity that is constantly changing in response to neural activity and other influences, and 
can vary in time from milliseconds to years 
1
. 
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Short-term synaptic plasticity includes facilitation, augmentation, potentiation and synaptic 
depression. Synaptic facilitation is a rapid increase in synaptic strength that occurs when two or 
more action potentials invade the presynaptic terminal within a few milliseconds of each other. 
Synaptic augmentation and potentiation are also elicited by repeated synaptic activity and serve to 
increase the amount of neurotransmitters released from presynaptic to postsynaptic terminals. 
Synaptic depression opposes facilitation, causing a decline of neurotransmitter release during 
sustained synaptic activity 
1
. 
Long-term synaptic plasticity includes LTP and LTD 
1
. LTP is a long-lasting increase in 
synaptic strength  due to certain patterns of high frequency electrical stimulation, whereas LTD is a 
long-lasting decrease in synaptic strength due to certain patterns of low frequency electrical 
stimulation 
1,2,4
, both of which are thought to be important for memory formation and storage in the 
brain 
5,12
. LTP and LTD are intimately related with the neuronal F-actin cytoskeleton. LTP can 
result in spine head enlargement accompanied by an increase in F-actin levels, whereas LTD 
results in shrinkage of dendritic spine heads and even spine elimination which is accompanied with 
actin depolymerization 
2,5,13
. Thus the G-actin/F-actin ratio and all the proteins that can interfere 
with the former affect the various aspects of dendritic spine morphology and consequently, 
synaptic plasticity 
2
. 
These enduring forms of synaptic plasticity (LTP and LTD) lead to protein phosphorylation 
and changes in gene expression which greatly outlast the period of synaptic activity and can yield 
changes in synaptic strength that persists for hours, days, or even longer. It is an important neural 
mechanism which modulates several forms of brain plasticity, such as learning new behaviours or 
acquiring new memories 
1
.  
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1.2. Protein Phosphatase 1 
Protein phosphatase 1 (PP1) is a Serine/Threonine (Ser/Thr) phosphatase that belongs to the 
phosphoprotein phosphatase superfamily along with PP2A, PP2B, PP4, PP5, PP6 and PP7 
14,15
. 
These phosphatases catalyze over 90% of all eukaryotic protein dephosphorylation reactions and 
among them, PP1 is the most important one in terms of substrate diversity, with close to 200 PP1-
interacting proteins (PIPs) have already been identified 
15
. 
PP1 is known to be involved in glycogen metabolism, transcription, protein synthesis, 
cellular division, meiosis and apoptosis. Additionally, through interaction with its regulatory 
proteins, PP1 can be involved in neurotransmission, neurite outgrowth and synapse formation 
16
. 
This versatility of PP1 is largely determined by the binding to different specific regulatory 
subunits, which can function as inhibitors of its activity, substrate-specifying subunits, targeting 
subunits or substrates. By interacting with its substrates, PP1 can dephosphorylate them at a single 
or multiple residues, activating or inactivating them. Some proteins can also mediate the targeting 
of PP1 to specific protein complexes, bringing PP1 in close proximity to specific substrates. PP1 
can also interact with proteins which enhance its activity towards a specific substrate, such as 
myosin phosphatase-targeting subunit 1 (MYPT1). Additionally, some proteins, such as dopamine- 
and cAMP-regulated neuronal phosphoprotein (DARPP-32) and inhibitors-1/2/3, can directly block 
PP1 activity, thus inhibiting the dephosphorylation of all PP1 substrates 
14–16
. 
1.2.1. PP1 isoforms 
The mammalian genome contains three different genes for PP1 (PPP1CA, PPP1CB and 
PP1CC) that encode four distinct catalytic subunits: PP1α, PP1β and the splice variants PP1γ1 and 
PP1γ2 14,17. 
PP1α, PP1β and PP1γ1 are ubiquitously expressed, while the PP1γ2 isoform is testis-
enriched and sperm-specific 
17,18
. Even though PP1α, PP1β and PP1γ1 are ubiquitously expressed, 
their expression levels differ, depending on the cell type and tissue 
18,19
. For instance, PP1α is more 
enriched in the brain (especially in the striatum and hippocampus) and in the heart; PP1β is more 
enriched in the brain, small intestine, muscle and lung; and PP1γ1 is more enriched in the brain 
(especially in the striatum and hippocampus), heart and skeletal muscle. Additionally, even in the 
same cell type, these isoforms have distinct localizations. In neuronal cells, PP1α is specially 
localized to dendritic spines, PP1β to the soma and dendritic shaft, and PP1γ1 to the dendritic 
spines and presynaptic terminals 
18,20
. 
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1.2.2. PP1 docking motifs 
As mentioned above PP1 has nearly 200 validated PIPs, and by using bioinformatics-assisted 
PIP identification screens it is estimated that hundreds more PIPs remain to be identified and 
validated. Moreover, PIPs interacts with PP1 in a highly specific manner, forming very stable 
complexes. This is due to PP1’s unique binding motifs, such as RVxF, SILK, MyPhoNE, 
“SpiDoC”, IDoHA, and others 14,15,21. 
Among these binding motifs, the RVxF motif is the most common, being present in nearly 
70-90% of all validated PIPs. This motif generally conforms to the consensus sequence 
[K/R][K/R][V/I][x][F/W], with x being any reside other than Phe, Ile, Met, Tyr, Asp or Pro. 
Interaction between PIPs and PP1 through this motif does not change PP1 conformation and only 
serves to anchor the PIPs to PP1, bringing them closer to PP1 and promoting secondary interactions 
that determine the activity and substrate specificity of PP1 
14,15,21
 (Figure 4). 
The SILK motif, [GS]IL[KR], initially described as being essential for PP1 inhibition by 
inhibitor-2, is present in seven PIPs and, as the RVxF motif, seems to be essential for PP1 
anchoring. The MyPhoNE motif, RxxQ[VIL][KR]x[YW] , is present in seven PIPs and is involved 
in substrate recognition. Both motifs (SILK and MyPhoNE) are always N-terminal to the RVxF 
14,15,21
. 
“SpiDoC”, is a domain in neurabin-2 which binds to the PP1 C-terminal groove, blocking 
access to substrates that require this groove for PP1 binding, thus directing the substrate specificity 
of PP1 
15,22
. This domain will be further explained in section 1.3.3. 
Aside from the RVxF and the SILK motif, inhibitor-2 has a third motif able to interact with 
PP1 – IDoHA. This motif binds PP1 in a manner that covers its active site, preventing all PP1 
activity 
14,15,23
. 
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Figure 4 – PP1 docking motifs. PP1 has several surface grooves that bind PIPs docking motifs 
(middle panel). Several proteins (gray, translucent structure) combine several PP1 docking sites to form 
unique combinations. Illustrations are based on known structures of PP1 with inhibitor-2 (A), Mypt (B), 
neurabin-2 (C) and neurabin-2 plus inhibitor-2 (D) (adapted from 
15
). 
  
11 
 
1.3. Neurabins 
1.3.1. Neurabin-1 
Neurabin-1 is a multifunctional scaffolding protein first identified and characterized in 1997 
from purified rat brain tissue 
24
. The human neurabin-1 is encoded by the PPP1R9A gene (protein 
phosphatase 1, regulatory subunit 9A) located on chromosome 7 
25
 and it is comprised of 1098 
amino acids (a.a.) 
26
. It has an N-terminal F-actin binding domain (a.a. 1-144), followed by a PP1 
binding domain (a.a. 425-502), a PDZ (PSD-95/Dlg/ZO-1) domain (a.a. 504-592), three C-terminal 
coiled-coil regions (a.a. 597-627, 670-824, 1033-1090) and a sterile alpha motif (SAM) domain 
(a.a. 988-1051) (Figure 5). These two latter domains are known to mediate homo- and 
heterodimerization of other proteins. Within the PP1-binding domain it is possible to identify a 
KIKF motif, conserved in other PP1 regulatory subunits 
27
. Neurabin-1 also has some consensus 
sequences for phosphorylation by several protein kinases 
28
. 
 
Figure 5 – Neurabin-1 domain structure. Coloured boxes represent the several domains found in 
neurabin-1. Vertical black lines represent the starting and ending a.a. of the respective domain. KIKF 
represents the RVxF motif found in neurabin-1. Dark blue, red and green vertical lines represent 
phosphorylation sites of ERK2, Cdk5 and PKA, respectively. N, N-terminal; C, C-terminal; ABD, F-actin 
binding domain; PP1, PP1 binding domain; PDZ, PSD-95/Dlg/ZO-1 domain; CC, coiled-coil domain; SAM, 
sterile alpha motif. 
Neurabin-1 is highly concentrated in the synapse and in the growth cone of developed and 
developing neurons, respectively 
24,29
. Initially thought to be neuron-exclusive, neurabin-1 was later 
found to be expressed both in the brain and skeletal muscle by northern blot 
30
. 
1.3.2. Neurabin-2 
Neurabin-2, also known as spinophilin, was initially identified and described in 1997 due to 
its ability to form a complex with the catalytic subunit of PP1 and due to its potent modulation of 
PP1 enzymatic activity in vitro 
31
. In humans it is encoded by the PPP1R9B gene located on the 
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chromosome 17 and it is comprised of 815 amino acids 
32
. It has two F-actin-, a receptor- and a 
PP1- binding domains, a LIZ and a PDZ domain, and three coiled-coil domains (Figure 6) 
32,33
. 
 
Figure 6 – Neurabin-2 domain structure. Horizontal lines represent the several domains of 
neurabin-2. Vertical lines represent phosphorylation sites. Light blue, green, dark blue and red represent 
phosphorylation sites of ERK2, Cdk5, PKA and CaMKII, respectively. RKIHF represents the RVxF motif 
found in neurabin-2. II, III and IV represent the several additional regions that can bind to PP1. N, N-
terminal; C, C-terminal; ABD, F-actin binding domain; RBD, receptor-binding domain; PP1, PP1-binding 
domain; LIZ, LIZ motif; PDZ, PSD-95/Dlg/ZO-1 domain. 
Neurabin-2’s F-actin-binding domain, a.a. 1-154, is intrinsically unstructured and upon 
binding to F-actin adopts a more ordered structure 
32,33
. Additionally, a second F-actin binding 
domain was described between a.a. 164-282. However it is still unknown whether these two 
domains represent segments of a single domain or two independent domains 
33,34
. 
The receptor-binding domain, located between a.a. 151-444, interacts with the third 
intracellular loop of various seven transmembrane domain receptors, such as the dopamine D2 
receptor and some subtypes of the α-adrenergic and muscarinic-acetylcholine receptors 32,33. 
The PP1-binding domain is located within residues 417-494 and contains the pentapeptide 
RKIHF motif between a.a. 447-451, conserved in other PP1 regulatory subunits 
32,33
. Within this 
domain it is possible to find other regions able to bind to PP1, as it will be described in section 
1.3.3 
22
. 
A LIZ motif was described between a.a. 485-510, known to mediate protein-protein 
interactions and target protein kinases and protein phosphatases to membrane ion channels. The 
PDZ domain, a.a. 494-585, directly binds to C-terminal peptides derived from glutamatergic 
AMPA and NMDA receptors. The three predicted coiled-coil domains between a.a. 664-814 allow 
for homo- and hetero- dimerization between neurabin-2 and other proteins. Neurabin-2 also has 
some consensus sequences for phosphorylation by several protein kinases 
32,33
. 
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Contrary to neurabin-1, neurabin-2 is ubiquitously expressed. It is highly concentrated in the 
brain tissue, especially in neurons, where it is enriched in the PSD 
35
. 
1.3.3. Neurabin-1 and neurabin-2 interactome 
As scaffolding proteins, both neurabin-1 and neurabin-2 interact with several proteins, 
dictating their localization within a cell (Table 1and Table 2). 
One of the most studied interactions of neurabin-1 and neurabin-2 is their interaction with 
PP1. The complex formed between neurabin-2 and PP1 is highly unique. Instead of binding to PP1 
using only its RVxF motif, neurabin-2 also binds to PP1 in three additional regions: a.a. 430-434 
and 456-460 (region II), a.a. 476-492 (region III) and a.a. 462-469 (region IV), with this latter 
interaction being necessary for directing the substrate specificity of PP1 (“SpiDoC”). Despite this 
extensive interaction surface, neurabin-2 does not bind PP1 near its active site leaving it unchanged 
and able to bind to other proteins, which likely explains how neurabin-2 can direct PP1 to a specific 
substrate, such as the AMPA receptor subunit, GluR1, present on the postsynaptic region of 
synapses 
22
. Ragusa et al., 2010, found that neurabin-1 and neurabin-2 had 100% primary sequence 
identity in the a.a. required for binding to the PP1 C-terminal groove 
22
, which suggests neurabin-1 
may also interact with PP1 in the same manner as neurabin-2. However, this has not yet been 
thoroughly investigated. 
How neurabin-2 can direct PP1 to a specific substrate has not yet been confirmed, however, 
a model has been proposed based on the following findings: neurabin-2’s PDZ domain is known to 
bind several proteins, including AMPA and NMDA receptor subunits; when PP1 is bound to 
neurabin-2, other proteins cannot bind to its PDZ domain, suggesting that neurabin-2 cannot have 
its PDZ- and PP1-binding domains simultaneously occupied; neurabin-2 is present in dimers, 
mediated by its coiled-coil domains. Thus, it has been proposed that one molecule of neurabin-2 
binds to PP1 through the PP1-binding domain and a second molecule binds to the subunits of the 
AMPA and NMDA receptors through its PDZ domain. Then, the two neurabin-2 molecules bind 
each other through their coiled-coil domains, bringing PP1 closer to the receptor, facilitating PP1 
dephosphorylation of AMPA and NMDA receptors. The same mechanism has also been proposed 
for neurabin-1 
36
. 
Other interactions will not be here fully described as this thesis is not related to them. 
However, the following tables (Table 1 and Table 2) summarize most of the known interactions 
between neurabins and other proteins in neurons, and their physiological roles. Neurabin-2 is 
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ubiquitously expressed and thus, can interact with several proteins not found in neurons 
32
, which 
are also not relevant for this thesis. For a more complete list, see Sarrouilhe and Ladeveze, 2014 
32
. 
Table 1 – Proteins able to interact with neurabin-1 in neurons 
Protein 
Neurabin-1 
motif 
Function References 
F-actin 
F-actin 
binding 
domain 
Binds to and binds other proteins to F-actin, regulating 
neuronal morphology. Promotes bundling and cross-linking of 
actin fibers. 
24,27,37–42
 
Neurabin-1 
Coiled-coil 
domain 
Can form homodimers dictating neurabin-1 effects on cell 
morphology. May facilitate interaction with other proteins. 
27,43–45
 
Neurabin-2 
Coiled-coil 
domain 
Can form heterodimers. Specific function of this interaction 
has not been yet investigated, but this interaction may 
negatively regulate neurabin-1/neurabin-2 effects on the 
neuronal cell. 
27,42
 
PP1α, PP1γ1 RVxF motif 
Directs PP1 to F-actin and to specific locations within the cell 
and regulates its localization and activity. Neurabin-1/PP1 
complex regulate synaptic transmission and bidirectional 
changes in hippocampal plasticity (enhancing LTD and 
inhibiting LTP), and are important in the formation of 
filopodia and dendritic spines. 
27,38–40,44,46
 
p70S6k PDZ domain 
Recruits p70S6k to the cytoskeleton at neuronal cell synapses, 
opposing neurabin-1/PP1 complex in regulating actin 
rearrangement and cell morphology. 
27,37
 
Kalirin-7 PDZ domain Regulation of actin cytoskeleton. 
47
 
Rac3 
Between a.a. 
472-513 
Mediates Rac3-induced neuritogenesis by anchoring Rac3 to 
growth cone F-actin. 
48
 
Lfc 
Coiled-coil 
domain 
Recruits Lfc, regulating Rho-dependent organization of F-
actin in spines leading to altered spine morphology. 
49
 
TGN38 
Coiled-coil 
domain 
May modulate the intracellular trafficking itinerary of TGN38. 
45
 
R4-RGS*, 
RGS19 
Not yet 
known. 
Opposes neurabin-2 binding to R4-RGS and RGS19, removing 
them from the GPCRs signaling complex and enhancing the 
intensity of Ca
2+
 signaling. 
50
 
I-2 (IPP-2) 
Between a.a. 
374-516 
Targets the PP1/I2 complex to F-actin, suggesting it regulates 
cytoskeletal functions and cell morphology. 
38
 
AMPA and 
NMDA  
receptor** 
PDZ domain 
Targets PP1 to these receptors regulating their phosphorylation 
state and activity. 
36
 
Abbreviations: a.a., amino acids; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; I-2 (IPP-
2), protein phosphatase inhibitor 2; Lfc, Rho guanine nucleotide exchange factor 2; NMDA, N-methyl-ᴅ-
aspartate; p70S6k, ribosomal protein S6 kinase beta-1; PP1, protein phosphatase 1; R4-RGS, R4 subfamily of 
RGS proteins; Rac3, ras-related C3 botulinum toxin substrate 3; RGS, regulators of G protein signaling; 
TGN38, trans-Golgi network integral membrane protein TGN38. 
*Only RGS1, RGS2, RGS4 and RGS16 were tested. 
** Subunits GluR2/3 and NR1C2’, NR2A/B and NR2C/D. 
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Table 2 – Proteins able to interact with neurabin-2 in neurons 
Protein Neurabin-2 motif Function References 
F-actin 
F-actin binding domain 1 and 
2 
Binds along the side of F-actin and has F-
actin-cross-linking activity. Directs 
several proteins to F-actin. It has a central 
role in actin organization. 
34,35,51–54
 
Neurabin-1 Coiled-coil domain 
Can form heterodimers. Specific function 
has not been yet investigated, but may 
negatively regulate neurabin-1/neurabin-2 
effects on the neuronal cell. 
27,42
 
Neurabin-2 Coiled-coil domain 
Can form homodimers, facilitating 
interaction with other proteins. 
45
 
PP1α, PP1γ1 
RVxF, region II, III and IV of 
the PP1-binding domain 
Forms very stable complexes with PP1, 
targeting it to dendritic spines and 
directing its substrate specificity. 
22
 
p70S6K* PDZ domain Unknown. 
55
 
R4-RGS**, 
RGS19 
Receptor-binding domain 
Recruits the RGS protein to the GPCRs 
signaling complex to reduce the intensity 
of Ca
2+
 signaling. 
50
 
Dcx Coiled-coil domain 
Enhances Dcx binding to F-actin and 
facilitates PP1-mediated 
dephosphorylation of Dcx. Neurabin-
2/Dcx complex may be involved in 
neuronal migration and dendritic spine 
formation. 
56–60
 
CaMKII 
C-terminal domain (non-
phosphorylated CaMKII) and 
between a.a. 151-300 (Thr286-
autophosphorylated CaMKII) 
Targets CaMKII to F-actin and targets 
PP1 to CaMKII. This interaction increases 
with neuronal maturation. 
61,62
 
I-2 (IPP-2) Between a.a. 354-494 
Targets the PP1/I2 complex to F-actin, 
suggesting it regulates cytoskeletal 
functions and cell morphology. 
38
 
TGN38 Coiled-coil domain 
May modulate the intracellular trafficking 
itinerary of TGN38. 
45
 
Tiam1 Between a.a. 444-817 
Promotes the plasma membrane 
localization of Tiam1 and enhances its 
ability to activate p70S6k. Suppresses 
Tiam1 ability to activate Pak1. 
63
 
3iL of α1BA, 
α2AA, α2BA and 
α2CA receptors 
Receptor binding domain 
Mediates regulation of α1BA receptor Ca
2+
 
signaling by RGS2, facilitating interaction 
of the latter with Gαq. May also contribute 
to the localization of these receptors. 
64–66
 
3iL of D2 
receptor 
Receptor binding domain 
May establish a signaling complex for 
dopaminergic neurotransmission through 
D2 receptors by linking them to 
downstream signaling molecules and the 
actin cytoskeleton. 
65,67
 
M1, M2 and 
M3 receptors 
Receptor binding domain 
Seems to recruit these receptors to the cell 
periphery. Regulates G-protein signaling 
by forming a complex with these receptors 
and RGS8. 
68,69
 
3iL of CCKA 
and CCKB 
receptor 
Not yet identified. 
May regulate G-protein signaling by 
binding to these receptors. 
50
 
AMPA and 
NMDA 
receptor*** 
PDZ domain 
Targets PP1 to these receptors regulating 
their phosphorylation state and activity. 
36,70
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Protein Neurabin-2 motif Function References 
δ- and μ-opioid 
receptor 
Receptor binding domain 
Attenuates agonist-driven ERK1/2 
phosphorylation mediated upon activation 
of the δ-opioid receptor, but not on μ-
opioid receptor. Modulates δ-opioid 
receptor signaling in a different manner 
that that of μ-opioid receptor. 
71
 
Abbreviations: 3iL, 3
rd
 intracellular loop; a.a., amino acids; α1/2-A/B/CAR, α-1/2-A/B/C adrenergic receptor; 
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; Ca2+, calcium; CAMKII, 
Calcium/calmodulin-dependent protein kinase type II; CCKA/B, Cholecystokinin receptor type A/B; D2, 
D(2) dopamine receptor; DCAMKL1, Serine/threonine-protein kinase DCLK1; Dcx, doublecortin; I-2 (IPP-
2), protein phosphatase inhibitor 2; M1/2/3, Muscarinic acetylcholine receptor M1/2/3; NMDA, N-methyl-ᴅ-
aspartate; p70S6k, ribosomal protein S6 kinase beta-1; PP1, protein phosphatase 1; R4-RGS, R4 subfamily of 
RGS proteins; Ras-GRF1, Ras-specific guanine nucleotide-releasing factor 1; RGS, regulators of G protein 
signaling; Tiam1, T-lymphoma invasion and metastasis-inducing protein 1; TGN38, trans-Golgi network 
integral membrane protein TGN38. 
*in vitro (P.E. Burnett and P.B. Allen, unpublished work). 
**Only RGS1, RGS2, RGS4 and RGS16 were tested. 
*** Subunits GluR2/3 and NR1C2’, NR2A/B and NR2C/D. 
 
  
17 
 
1.4. PP1, neurabin-1 and neurabin-2 in dendritic spines 
As aforementioned, PP1 is ubiquitously expressed. However, in the brain, more specifically, 
in neurons, PP1α and PP1γ1 isoforms are highly localized to dendritic spines 18,20.  PP1 has been 
identified as a key regulator in both LTP and LTD, with PP1 inhibiting LTP while promoting LTD. 
In fact, LTD-inducing stimuli promotes distribution of PP1 to dendritic spines, where it can 
dephosphorylate its substrates, such as calcium/calmodulin-dependent protein kinase II (CaMKII), 
AMPA and NMDA receptors 
27,72
.  
Neurabin-1 is highly concentrated in dendritic spines, even though it can be found in 
dendrites, axons, terminals and glia. Within dendritic spines, neurabin-1 can be found at high levels 
in the PSD and the 100 nm subjacent to it. In fact, neurabin-1 concentration falls with increasing 
distance from the synapse 
29
. Neurabin-1 knockout mice exhibited a deficit in contextual fear 
memory and increased AMPA receptor synaptic transmission, suggesting neurabin-1 regulates LTP 
12
. Additionally, neurabin-1 overexpression induced filopodia and dendritic spines 
27
, further 
suggesting that it has an important role in spine morphogenesis. 
Neurabin-2 is highly enriched at the synaptic membrane in dendritic spines, where it 
regulates the actin cytoskeleton. Within dendritic spines, neurabin-2 localization is similar to that 
of neurabin-1. It is predominantly localized in the PSD and the subjacent 100 nm of it, with its 
concentration decreasing with increasing distance from the synapse 
73
. Knockout mice exhibited a 
marked increase in spine density during development and altered filopodia formation, suggesting it 
functions as a negative regulator of spine morphogenesis 
33,42,52
.  
Neurabin-1 and neurabin-2 can form hetero- and homodimers and rapidly shuttle on and off 
the actin cytoskeleton. Through interaction with their respective partners (Table 1 and Table 2), 
they are able to regulate spine morphology and density, receptor function and synaptic plasticity 
38
. 
They bind an overlapping set of targets with some opposing effects, as can be observed in both 
Table 1 and Table 2. Also, as beforementioned, neurabin-1 overexpression induced filopodia and 
dendritic spines 
27
 while neurabin-2 knockout mice exhibited a marked increase in spine density 
during development 
52
. Additionally, neurabin-1 and neurabin-2 seem to have opposing effects on 
the regulation of R4-RGS 50,65. Due to all these opposing effects, it has been proposed that 
neurabin-1 and neurabin-2 may act as negative regulators of each other, especially in dendritic 
spines, where they are highly concentrated. 
Both neurabins were initially identified as being PP1-targeting subunits. However, between 
PP1 isoforms, both neurabins showed a significant preference for PP1γ1 and PP1α over PP1β 44. 
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Since neurabins showed enhanced localization to dendritic spines 
29,73
, this preference is to be 
expected, as both PP1γ1 and PP1α are enriched in dendritic spines, while PP1β is more enriched at 
the neuronal cell body 
44
. 
Disrupting the neurabins/PP1 complex prevents PP1 from reaching some of its targets, thus 
preventing PP1-mediated dephosphorylation of its substrates. The neurabin-1/PP1 complex is 
important in the formation of filopodia in young neurons and the transformation of neuronal 
filopodia into dendritic spines, since it has been shown that disruption of this complex enhances 
filopodia and impairs surface GluR1 expression, hindering the morphological and functional 
maturation of dendritic spines 
39
. Neurabin-2 targets PP1 to several substrates in dendritic spines 
(such as AMPA and NMDA receptors), controlling their phosphorylation states 
52
 and blocking the 
neurabin-2/PP1 complex prevents PP1-mediated dephosphorylation of the AMPA receptors, 
decreasing the rundown of AMPA currents and increasing the latter’s activity 70. 
The neurabins/PP1 complex can be disrupted by phosphorylation. It has been shown that 
cAMP-dependent protein kinase catalytic subunit alpha (PKA) phosphorylation of neurabin-1 at 
Ser-461 (near the RVxF site) results in the drastic reduction of PP1 affinity 
27,46
, allowing neurabin-
1 recruitment of other proteins 
27
. Even though the RVxF-flanking serine of neurabin-1 is 
conserved in neurabin-2, PKA does not phosphorylate neurabin-2 at the same site. Instead, it 
phosphorylates a serine residue in the F-actin binding domain (Ser-94; in rat, PKA can also 
phosphorylate Ser-177) 
16,32,54
. This does not result in reduced PP1 affinity for neurabin-2, but does 
reduce neurabin-2 interaction with F-actin, displacing neurabin-2 from the PSD to the cytosol, 
which may ultimately serve to control PP1-mediated changes in the actin cytoskeleton or PP1 
anchoring to receptors 
54
. 
Neurabin-1 and neurabin-2 share a conserved site at Ser-17 for cyclin-dependent-like kinase 
5 (Cdk5) phosphorylation. However, different research groups reached two different conclusions 
on neurabin-1 phosphorylation by Cdk5.  Futter et. al, 2005 has shown that neurabin-1 can be 
phosphorylated by Cdk5 at Ser-17 in vitro 
28
, while Causeret et. al, 2007 did not, reporting Cdk5 
phosphorylation at Ser-95 instead 
74
. This latter research group found that Ser-95 phosphorylation 
of neurabin-1 affects its ability to bind to F-actin, thus regulating neuronal morphology 
74
. As for 
neurabin-2, Cdk5 phosphorylation at Ser-17 did not affected its ability to bind to F-actin, while 
extracellular signal-regulated kinase 2 (ERK2) Ser-15 phosphorylation did 
28
. This latter kinase can 
also phosphorylate neurabin-1 at Ser-15, at least in vitro. However, the effect of this 
phosphorylation was not tested 
28
. 
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Additionally, neurabin-2 can also be phosphorylated by CaMKII (Ser-100 and Ser-116), 
which, as with PKA phosphorylation at Ser-94, reduces neurabin-2 ability to bind to F-actin. 
Neurabin-2 phophorylated at Ser-100 showed enhanced concentration in membrane fractions, 
including the synaptosomal membrane and synaptic plasma membrane. Both CaMKII and PP1 are 
enriched in the PSD (with the latter being bound to neurabin-2 which, in turn, is bound to F-actin). 
CaMKII is autophosphorylated at Thr-286, a critical process for the regulation of synaptic 
signaling, and PP1 selectively dephosphorylates phospho-Thr-286 CaMKII, preventing its 
association with NMDA and AMPA receptors. So, CaMKII phosphorylation of neurabin-2 may 
reduce the interaction between the neurabin-2/PP1 complex with F-actin, thus preventing PP1 from 
dephosphorylating phospho-Thr-286 CaMKII 
62
. 
Moreover, neurabin-2 localization was shown to vary depending on the kinase that 
phosphorylates it 
28,54,62
. Thus, it has been suggested that phosphorylation of neurabin-2 regulates 
subcellular localization of the neurabin-2/PP1 complex, targeting this complex to specific locations 
within dendritic spines 
28,62
. Finally, since neurabin-1 can also be phosphorylated by PKA 
46
, ERK2 
 
and Cdk5 
28,74
, but not CaMKII 
62
, it has been suggested that both neurabin-1 and neurabin-2 
scaffolding functions are differentially regulated by phosphorylation 
28,62
. 
Concluding, neurabin-1 and neurabin-2 are scaffolding proteins which can target PP1 (and 
also other proteins) to different locations within dendritic spines. They seem to act as opposing 
regulators of each other since they have opposing effects on the actin dynamics of dendritic spines 
and regulation of R4-RGS. Additionally, their localization, and consequently PP1 localization, 
changes whether they are phosphorylated or not, which may explain how they can target PP1 to 
specific substrates within different cellular compartments. 
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1.5. Alzheimer’s disease 
Alzheimer’s disease (AD) is the commonest neurodegenerative disorder afflicting our older 
population, contributing to 50-75% of all dementia cases 
75,76
. It affects more than 5 million 
Americans 
76,77
 and almost 100000 Portuguese 
78. Since our population’s average life expectancy is 
increasing, these numbers are expected to more than double by 2050, making it a major and 
growing public health concern 
76,78
. 
AD was first characterized in 1907 by Alois Alzheimer, who identified a patient with 
memory impairment, disorientation both in time and space, and hallucinations. The postmortem 
examination showed an evenly atrophic brain, the presence of several fibrils and the deposition of a 
pathological metabolic substance 
79
. 
Since then, our understanding of the pathological lesions associated with this condition 
improved. However, as of today, there is still no cure and our understanding of the development of 
this disease still has a lot of gaps which need to be filled 
76,80
. Currently, it is known that the core 
clinical features of AD include gradual and progressive decline in memory, executive function and 
ability to perform daily activities; however, the disease progresses differently among different 
individuals 
77,81
, with some of them showing signs of hallucinations and paranoia while others do 
not 
81
. Histopathologically, AD is characterized by the presence of extracellular amyloid plaques 
(senile plaques) and intracellular neurofibrilliary tangles 
81,82
. 
Senile plaques are deposits of small peptides – amyloid β peptide (Aβ) – derived via 
sequential proteolytic cleavages of the amyloid β precursor protein (APP) 83. Neurofibrilliary 
tangles comprise paired helical tau filaments, a microtubule binding  and stabilizing protein 
81
. 
Aside from these two major changes, AD can also be characterized by neuronal and dendritic loss, 
neuropil threads, dystrophic neurites, granulovacuolar degeneration, Hirano bodies and 
cerebrovascular amyloid 
82
. 
1.5.1. AD Forms 
There are two forms of AD, the familiar form and the sporadic form, both of which are 
clinically and histopathologically undistinguishable 
84
. The familiar form affects 1% of the patients 
and has an earlier onset and much more rapid progression than the more common sporadic form 
85
. 
It was the familiar form of AD that brought attention to the Aβ in its pathogenesis since mutations 
associated with this form were present in the APP gene and in the presenilin genes, PSEN1 and 
PSEN2. Inheriting any of these mutations guarantees that the individual will develop AD later in 
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life. The PSEN mutations alter the γ-secretase-mediated proteolytic cleavage of APP, leading to an 
increase in the production of the more toxic form of Aβ 84,86. 
The sporadic form, which accounts for nearly 99% of the cases, is not directly associated 
with any known mutation  and probably involves several different etiopathogenic mechanisms or 
risk factors 
85
. 
1.5.2. AD risk factors 
Advanced age is the greatest risk factor for AD. Additionally, the risk of developing the 
disease is greater for those individuals who already have a mild cognitive impairment, little to no 
social and cognitive engagement, moderate to severe brain injury, cardiovascular disease, 
hypertension, type II diabetes, obesity and dyslipidemia. It is currently unknown whether smoking 
increases, decreases or has no association with the risk of developing AD 
76,86,87
. 
Aside from the mutations associated with the familiar form of AD, there are other genetic 
factors that represent a higher risk of developing the disease. To date, the major risk factor 
described is the ε4 allele of the apolipoprotein E (Apo E) gene (the remaining ε2 and ε3 alleles are 
protective and neutral, respectively) 
76,86,87
. Additionally, mutations in the SORL1, CLU, PICALM, 
CR1 or BIN1 are also associated with an increased risk of developing AD 
86,87
. 
There are also protective factors associated with AD. Physical activity and consumption of a 
Mediterranean diet are known protective factors against heart diseases and also improve overall 
brain health, thus being factors that also decrease the risk of developing AD and other dementias 
86,87
. 
1.5.3. Alzheimer’s disease pathology 
AD’s major hallmarks are, as mentioned above, the presence of extracellular senile plaques 
and intracellular NFTs. Arising from the existence of these two major changes came two different 
lines of thought: the first proposes that AD starts with the accumulation of Aβ while the second 
proposes that it all starts with hyperphosphorylated tau 
88
. However, the first hypothesis has been 
the predominant model to explain the molecular pathogenesis in AD, since it has been found that 
mutations causing the familiar form of AD result in a similar biochemical phenotype (increased 
Aβ42/Aβ40 ratio) 
89
. This hypothesis states that the impaired production of Aβ species, and the 
subsequent imbalance between Aβ generation and clearance, triggers several events that disrupt 
neuronal homeostasis (mitochondrial dysfunction, activation of oxidative stress and inflammatory 
cascades, decreased neuroplasticity, hyperphosphorylation of tau protein and apoptosis). These 
22 
 
events then culminate with neuronal death, and the subsequent clinical features associated with the 
disease 
90
. 
1.5.4. APP 
In mammals, APP belongs to a protein family that includes APP-like protein 1 (APLP1) and 
2 (APLP2). It is a type-1 integral membrane protein containing a large extracelullar domain, a 
hydrophobic transmembrane domain and a short intracellular domain, designated the APP 
intracellular domain (AICD). APP is encoded by a gene located on chromosome 21 that can 
undergo alternative splicing generating 8 isoforms, three of which are most common: APP695, 
APP751 and APP770. APP695 is predominantly expressed in neurons, while APP751 and APP770 
are more ubiquitously expressed 
91,92
. Unlike all other isoforms, APP695 does not contain a 56 a.a. 
domain, the Kunitz protease inhibitor (KPI) domain. Some reports have shown that APP isoforms 
containing the KPI domain are elevated in AD patients and other studies have shown that 
prolonged activation of NMDA receptor in neurons can shift APP expression from APP695 to KPI-
containing APP isoforms which is accompanied by increased Aβ production 83,93. 
APP can undergo posttranslational processing via two major pathways: the non-
amyloidogenic pathway and the amyloidogenic pathway (Figure 7). In the non-amyloidogenic 
pathway, APP is initially cleaved by α-secretase, producing a membrane associated C-terminal 
fragment consisting of 83 a.a. (C83) and a large N-terminal ectodomain fragment (sAPPα) which is 
released into the extracellular space. C83 is then cleaved by γ-secretase, giving rise to the small 
peptide P3, and AICD, both of which are quickly degraded 
83,89,91,92
. 
In the amyloidogenic pathway, APP is initially cleaved by β-secretase, which gives rise to a 
membrane associated C-terminal fragment of 99 a.a. (C99) and sAPPβ, which is released into the 
extracellular space. C99 is then further cleaved by γ-secretase, releasing AICD and the Aβ peptide 
83,89,91,92
. Most of the Aβ produced is the variant of 40 residues (Aβ40) but a longer form of 42 
residues (Aβ42) can also be produced (depending of the γ-secretase exact cleavage site 
92
), which is 
more hydrophobic and thus, more prone to aggregation, being the predominant form present in 
senile plaques 
89
. 
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Figure 7 – APP processing. APP can be cleaved by α- or β-secretase, resulting in the secretion of 
sAPPα or sAPPβ, respectively. The remaining C-terminal fragments, C83 or C99 are further cleaved by γ-
secretase, releasing AICD and p3 or Aβ. Depending on the exact site of γ-secretase cleavage the Aβ produced 
may have 40 (Aβ40) or 42 (Aβ42) a.a. (adapted from 
92
). 
APP and its products have important physiological functions. APP is widely accepted as a 
protein that contributes to cell adhesion via its extracellular domain. The secreted sAPPα has been 
found to be neuroprotective and is thought to promote neurite outgrowth and synaptogenesis as 
well as contributing to cell adhesion. sAPPβ only lacks 17 a.a. compared to sAPPα, however it 
lacks most of the latter’s neuroprotective effects. In fact, a study suggested that sAPPβ can be 
cleaved and stimulate axonal pruning and neuronal cell death. Since AICD is quickly degraded its 
functions are very difficult to study, however, it has been proposed that it is important in 
transcription activation and neurite outgrowth 
93
. 
1.5.5. Aβ peptide 
AD patients are characterized by the extracellular deposition of insoluble aggregates of the 
Aβ peptide, which supports the idea that this peptide is essential in the pathogenesis of the disease. 
However, it was shown that the Aβ peptide in its soluble form is also produced under normal 
physiological conditions during cellular metabolism. In a healthy brain it is possible to identify 
different Aβ species (Aβ40 and Aβ42) at low levels, which suggests they may have important 
physiological functions 
89,94
. 
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It was demonstrated that endogenous Aβ is required for the induction of LTP in the 
hippocampus as well as for the induction of memory 
89,94, and inhibition of Aβ production induces 
cell death. It was proposed that Aβ could have a negative feedback function preventing 
excitotoxicity, since it was demonstrated that increased neuronal activity can enhance the 
production of Aβ which, in turn, depresses synaptic function, decreasing neuronal function 89. 
However, despite its possible important physiological roles, Aβ is still widely considered to 
be the main pathological agent causing AD. Asides from being found in postmortem brains of AD 
patients, several studies linked Aβ with the major pathological characteristics of this disease, 
including synaptic toxicity, derangement of the neuronal network and consequently, the 
progressive memory loss associated with the disease 
89,95
. 
As aforesaid, both soluble Aβ40 and Aβ42 can be identified even in healthy brains. However, 
when these peptides form insoluble oligomers they become extremely toxic. Aβ42 in particular, is 
more amyloidogenic and more prone to form aggregates than Aβ40 
89,95
. These aggregates were 
found to block LTP in the hippocampus of rats by binding and cross-linking receptors which are 
then internalized and degraded in the postsynaptic neuron 
94,95. Particularly, Aβ can lead to synaptic 
activation of caspase 3 which, in turn, activates calcineurin that dephosphorylates GluR1 subunit of 
AMPA receptors, leading to their removal from postsynaptic sites 
89,95
. These postsynaptic changes 
lead to a decrease of LTP and/or an increase of LTD, thus leading to an impairment of synaptic 
plasticity and to a progressive degeneration of synapse 
89
. 
Asides from interfering directly with receptors, Aβ can interfere with mitochondria in 
neurons. Mitochondrial dysfunction is implicated in AD and several other neurodegenerative 
diseases and Aβ was found to be within mitochondria in postmortem brains from AD patients. It 
was found that Aβ induces mitochondrial dysfunction and promotes mitochondrial fragmentation 
(fission/fusion balance impairment) 
89,95
, leading to an increased mitochondrial outer membrane 
permeability and consequently to cytochrome c (Cyt c) release to the cytosol. Cytosolic Cyt c 
induces the formation of apoptosome and consequent activation of executioner caspases, including 
caspase 3, which ultimately lead to alterations of basal synaptic transmission, enhancement of 
LTD, dendritic spine degeneration and behavioral impairment. Additionally, Aβ accumulation may 
impair the clearance of damaged organelles and proteins (reduced lysosomal degradative 
efficiency), which results in increased oxidative damage, accumulation of more damaged 
organelles, decreased adenosine 5'-triphosphate (ATP) production, release of apoptotic factors and, 
ultimately, neuronal death 
89
. 
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2. Aims 
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AD is a neurodegenerative disorder characterized by a gradual and progressive decline in 
memory, executive function and ability to perform daily activities. These symptoms are the effect 
of synaptic loss and ultimately neuronal death, thought to be triggered by the neurotoxicity of Aβ. 
Thus, studying the proteins involved in the formation and maintenance of dendritic spines (site of 
the majority of synapses) can help to understand the synaptic loss seen in AD. 
The main aim of this thesis was to evaluate the effects of Aβ on two proteins known to be 
involved in dendritic spine morphogenesis and dynamics (neurabin-1 and neurabin-2) and their 
interaction with PP1. 
The specific objectives were to: 
 study the effects of Aβ on the expression of neurabin-1 and neurabin-2; 
 evaluate the effects of Aβ on the interaction of neurabin-1 and neurabin-2 with PP1; 
 assess the normal cellular distribution of neurabin-1 and neurabin-2 in SH-SY5Y 
cells; 
 evaluate the effects of Aβ on the cellular distribution of neurabin-1 and neurabin-2.
  
  
29 
 
3. Materials and Methods 
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3.1. Antibodies 
Antibodies are a pivotal reagent in many laboratorial techniques. They are host proteins 
produced in response to the presence of foreign molecules in the body which can recognize a 
unique part in the foreign molecule - antigen. They have a constant region (Fc) and a variable 
region (Fab). This latter region binds to a certain epitope of the antigen, which gives each antibody 
its specificity 
96,97
. 
They can be classified as polyclonal or monoclonal antibodies (Figure 8). Polyclonal 
antibodies contain multiple clones of antibodies produced to different epitopes on the antigen, 
while monoclonal antibodies contain a single antibody from one clone of B-cells to a single epitope 
on the antigen. Thus, polyclonal antibodies are more sensitive, as they can bind to several epitopes 
giving a larger signal, but are less specific (can bind unspecifically to other proteins that share the 
same epitope) than monoclonal antibodies, which are highly specific but less sensitive 
96,97
. 
 
Figure 8 – Monoclonal and polyclonal antibodies. Monoclonal antibodies (left) can only bind to a 
specific epitope, while polyclonal antibodies (right) can bind to several different epitopes (adapted from 
97
). 
The following tables (Table 3 and Table 4) summarize the different antibodies used in this thesis. 
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Table 3 – Primary antibodies and specific dilutions used 
Antibody Antibody type Target Dilution 
Anti-Neurabin-I (D-4) 
(Santa Cruz 
Biotechnology, Inc.) 
Mouse, polyclonal Neurabin-1 
WB: 1:100 
ICC: 1:50 
Anti-PPP1R9B 
(Proteintech) 
Rabbit, polyclonal Neurabin-2 
WB: 1:1000 
ICC: 1:100 
Anti-PP1α (CBC2C)19 Rabbit, polyclonal PP1α 
WB: 1:2500 
ICC: 1:250 
Co-IP: 4 μl/1000 μg 
Anti-PP1γ (CBC3C)19 Rabbit, polyclonal PP1γ 
WB: 1:5000 
ICC: 1:500 
Co-IP: 3 μl/1000 μg 
Anti-β3-tubulin 
(Millipore) 
Mouse, monoclonal β3-tubulin WB: 1:1000 
Anti-MAP2 
(Calbiochem) 
Mouse, monoclonal MAP2 WB: 1:500 
Abbreviations: Co-IP, co-immunoprecipitation; ICC, immunocytochemistry; WB, western blot 
 
Table 4 – Secondary antibodies used 
Antibody Target Dilution 
Horseradish peroxidase-
conjugated anti-mouse 
(Amersham Pharmacia) 
Anti-mouse primary antibodies 1:5000 
Horseradish peroxidase-
conjugated anti-rabbit (Amersham 
Pharmacia) 
Anti-rabbit primary antibodies 1:5000 
 
3.2. Cell culture 
3.2.1. Culture, growth and maintenance of SH-SY5Y cell line 
The SH-SY5Y neuroblastoma cell line was chosen since it is human derived and can be 
differentiated to a more mature neuronal-like phenotype. Originally derived from a metastatic bone 
tumor biopsy, SH-SY5Y cells are a subline of the parental line SK-N-SH, which were subcloned 
three times: first to SH-SY, then to SH-SY5, and finally to SH-SY5Y 
98
. 
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SH-SY5Y cells (ATCC® CRL-2266™) were grown and maintained in Minimal Essential 
Medium (MEM)/F12 (1:1) medium supplemented with 10% fetal bovine serum (FBS), 0.5 mM L-
glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. Cultures were maintained at 37°C 
under 5% CO2. Cells were subcultured whenever 80-90% confluence was reached. 
3.2.2. Differentiation of the SH-SY5Y cell line 
SH-SY5Y can be differentiated into a more mature, neuronal-like phenotype through the 
addition of several different compounds into their medium. One of the most commonly used and 
best characterized methods for induction of differentiation in SH-SY5Y cells, is the addition of 
retinoic acid (RA) to the culture medium. RA is a vitamin A derivative known to possess growth-
inhibiting and cellular differentiation-promoting properties. Usually, RA is administered at a 
concentration of 10 μM in serum-free or low serum medium to induce differentiation. However, it 
is possible to find in the literature several variations of this differentiation medium, with some 
research groups using medium with different concentrations of serum and/or by administering RA 
for different number of days 
98
. Due to all of these variations, it was decided to test several different 
combinations of FBS and RA in the media in order to optimize the differentiation parameters, as 
depicted in Table 5. 
Table 5 – Different combinations of FBS and RA used in the experiments 
Media FBS (%) RA (μM) 
A 10 10 
B 10 20 
C 3 10 
D 3 20 
E 1 10 
Abbreviations: FBS, fetal bovine serum; RA, retinoic acid 
 
All the remaining constituents of the media are the same as described in section 3.2.1. SH-
SY5Y cells were differentiated with these different combinations of FBS and RA for 10 days, with 
the media being renewed every 2 days. 
To confirm whether the tested conditions were capable of inducing differentiation, controls 
were grown in the same media without the addition of RA. 
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3.2.3. Culture, growth and maintenance of rat primary cultures 
Experiments were also carried out in rat primary hippocampal cultures, provided by a 
laboratory colleague. The hippocampus was dissected from Wistar Hannover rat embryo at 18
th
 day 
of gestation and dissociated with trypsin (2.25 mg/mL) and deoxyribunoclease I (1.5 mg/mL) in 
Hank's Balanced Salt Solution (HBSS) for 5 minutes at 37°C. Cells were washed with HBSS 
supplemented with 10% FBS to stop trypsinization, centrifuged at 1000 rpm for 2 minutes, and 
further washed and centrifuged with HBSS for serum withdraw. Cells were plated onto poli-D-
lysine coated dishes at a density of 1.0x10
5
 and cultured for 10 days in Neurobasal medium (Gibco) 
supplemented with 2% B27 (Gibco), a serum-free medium combination. The medium was further 
supplemented with glutamine (0.5 mM), gentamicin (60 μg/mL), and glutamante (25 μM). Cells 
were maintained in an atmosphere of 5% CO2 at 37°C and observed in an inverted optical 
microscope. Five days after plating, 25% of culture medium was replaced with glutamate-free 
complete Neurobasal medium. After 10 days in culture, cells were used for experimental 
procedures.  
3.2.4. Aβ treatment of SH-SY5Y cell line and rat primary cultures 
To evaluate the effects of Aβ on the expression and interaction of several proteins, 
differentiated SH-SY5Y cells and rat primary hippocampal cultures were incubated with different 
concentrations of Aβ peptide for 24 hours. 
Synthetic Aβ1-42 (American Peptide) was dissolved in water to prepare 1 mM stock 
solutions. Exposure of cells to these Aβ peptides was preceded by an aggregation step, which 
was achieved by incubating the peptides for 48 hours at 37°C with phosphate buffered saline 
(PBS) 1x at concentration of 100 μM 99. 
SH-SY5Y cells were incubated for 2 days with media E (Table 5) and then incubated for 24 
hours in serum free Minimal Essential Medium (MEM)/F12 (1:1) medium supplemented with 0.5 
mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin and 10 μM RA with different 
Aβ1-42 peptide concentrations: 2 μM Aβ1-42 and 10 μM Aβ1-42. Prior to Aβ1-42 treatment, cells were 
washed twice with PBS 1x. 
Rat primary hippocampal cultures were plated as described in section 3.2.3 and washed 
twice before treatments. Cells were incubated with 2 μM Aβ1-42 and 10 μM Aβ1-42 for 24 hours in 
a B27-free Neurobasal medium combination. 
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Control cultures in both cell lines received PBS 1x vehicle. This was to ensure that the 
results obtained were not due to the PBS, which was used to aggregate the Aβ1-42 peptide, but 
due to the peptide itself. 
3.2.5. Cell Collection and Protein Quantification 
Cells were collected using different methods depending on the experimental procedure. 
To analyze protein expression, cells were collected using 140 μl of sodium dodecyl sulfate 
(SDS) 1%. SDS is a strong ionic detergent, able to solubilize lipids and proteins in the membrane 
of cells, creating pores within the membrane and eventually leading to full cell lysis 
97
.The 
resulting lysates were subjected to western blot analysis. 
For the purpose of testing protein interactions through co-immunoprecipitation (Co-IP), cells 
were collected using lysis buffer (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 4% CHAPS) containing 
protease inhibitors (0.5 mM PMSF, 1 mM Benzamidine, 10 μM Leupeptin, 20 μg/mL Aprotinin, 1 
μM Pepstatin A, 1 mM Sodium Fluoride, 1 mM Sodium Orthovanadate), to prevent proteolysis, 
dephosphorylation and denaturation of proteins. 
Following cell collection and protein extraction, protein concentration of each sample was 
assessed through Pierce’s bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) following 
the manufacturer’s instructions. This assay combines the reduction of Cu2+ to Cu1+ by protein in an 
alkaline medium with the highly sensitive and selective colorimetric detection of Cu
1+
 by 
bicinchoninic acid 
100
. This procedure was performed in a 96-well plate for spectrophotometric 
analysis. Standard samples were prepared using known amounts of bovine serum albumin (BSA), 
as depicted in Table 6. The remaining samples were prepared by mixing 5 μL of the cell lysate with 
20 μL of 1% SDS. Following preparation of the samples, 200 μL of working reagent was added to 
each well. The working reagent was prepared by mixing BCA reagent A with the BCA reagent B in 
a 50:1 proportion. The 96-well plate was then incubated for 30 minutes at 37°C, after which the 
absorbance was measured at 562 nm using a microplate reader (Infinite M200, Tecan). A standard 
curve was obtained by plotting standard absorbance vs BSA concentration, and used to determine 
the total protein concentration of each sample. 
Duplicates of all samples were assayed by this method. 
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Table 6 – Protein standards used in BCA Protein Assay method 
Standard BSA (μL) 1% SDS (μL) Protein Mass (μg) 
P0 0 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
Abbreviations: BCA, bicinchoninic acid; BSA, Bovine Serum Albumin; SDS, Sodium Dodecyl Sulfate 
 
3.3. Co-immunoprecipitation 
To test whether Aβ influences the interaction between PP1 (both α and γ isoforms) and 
neurabin-1 and neurabin-2, a co-immunoprepitation (Co-IP) was performed using SH-SY5Y cells. 
This technique is a variant of immunoprecipitation and relies on the immunodepletion of a protein 
of interest (“bait”) together with all its protein interacting partners (“prey”) in solution 101. 
In the experimental procedure the Co-IP was carried out using Dynabeads® Protein G 
(Invitrogen) because magnetic bead-based separation is rapid and easy to perform, allows for gentle 
separation which preserves most protein-protein interactions, and significantly reduces background 
caused by non-specific binding. The procedure is based on the ability of Dynabeads® Protein G to 
bind to a primary antibody through their Fc region 
102
. These antibody-bound magnetic beads are 
then placed on a Dynal magnet, which causes these beads to migrate to the side of the tube facing 
the magnet, allowing for easy removal of the supernatant. A sample of proteins is then added to 
these magnetic beads which permits that the bait in the sample, and consequently any bait-prey 
complex, bind to the antibody-bound magnetic beads. Then, by using the Dynal magnet and 
removing the supernatant, only the bait-prey complex is left, which can then be analyzed 
101,102
. In 
the experimental procedure here used, this complex was analyzed through SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
Cell culture was performed as described in section 3.2.4 in 100 mm culture dishes with 
media E (Table 5). Following 24 hours of Aβ treatment, media were removed, cells were washed 
with cold PBS 1x and then gently scrapped off the culture plate with lysis buffer (50 mM Tris-HCl 
pH 8, 120 mM NaCl, 4% CHAPS) containing protease inhibitors (0.5 mM PMSF, 1 mM 
Benzamidine, 10 μM Leupeptin, 20 μg/mL Aprotinin, 1 μM Pepstatin A, 1 mM Sodium Fluoride, 1 
mM Sodium Orthovanadate). Lysates were collected and then sonicated twice for 10 seconds. 
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Each sample had its mass normalized using the BCA assay described in section 3.2.5 and 
1000 μg of each was then precleared with 15 μL Dynabeads for 1 hour at 4°C with agitation. In a 
separate microtube, 40 μL of Dynabeads were added to 200 μL of washing solution (to ensure 
proper agitation) with the primary antibody (PP1α and PP1γ at respective dilutions, depicted in 
Table 3) for 1 hour at 4°C with agitation. Prior to use, Dynabeads were washed thrice with washing 
solution (3% BSA/PBS) and then stored at 4°C. 
After 1 hour, each sample was transferred to the antibody-containing microtube, previously 
washed with 200 μL of washing solution, and were then incubated overnight at 4°C with agitation. 
Following the incubation period, the supernatant was removed and the beads washed thrice with 
500 μL of PBS 1x for 10 minutes at 4°C with agitation. After the last wash, the supernatant was 
fully discarded and the beads resuspended in 100 μL of 1x Loading Buffer (LB) and boiled for 10 
minutes at 90°C for disruption of the Dynabead-proteins complex. Dybabeads were removed and 
samples were stored at -20°C until needed. 
Co-IP controls were performed by incubating cell extracts with Dynabeads without antibody. 
3.4. Western Blot 
Western blot (WB), also known as immunoblot, is a widely used technique for the detection 
and analysis of proteins. It involves several steps which allow for the detection and analysis of the 
protein of interest. Initially, samples need to be prepared, then separated on an electrophoresis gel 
and finally transferred onto a nitrocellulose membrane. After transfer, membranes are incubated 
with antibodies, detected and finally analyzed 
97
. 
In the present work electrophoresis gels were 5-20% gradient SDS-PAGE, a denaturing gel, 
which allows for separation of proteins solely on the basis of their molecular weight. It consists of 
two gels, a resolving (bottom), with higher concentration of polyacrylamide to separate proteins, 
and a stacking (top) gel, with lower concentration of polyacrylamide 
97
. 
Prior to loading the samples, a loading buffer is added, which consists of glycerol, SDS, a 
reducing agent (β-mercaptoethanol) and a dye (bromophenol blue). Glycerol increases density to 
the samples and helps anchor the sample in the wells; SDS masks any inherent charge of the 
proteins; the reducing agent breaks any disulfide bonds, disrupting quaternary and tertiary protein 
structures; and the dye enables tracking of the progression of the sample in the gel 
97
. 
Electrical current is then applied to the gel, enabling the separation of proteins. After 
separation, the proteins are transferred electrophoretically onto a nitrocellulose membrane. This 
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immobilized all proteins that were initially loaded into the gel, at their respective relative migration 
positions at the time point when the electric current of the gel run was stopped 
97
. 
Following transfer, membranes can be stained with Ponceau S to confirm whether the 
proteins were transferred and assess equal gel loading. Membranes are then blocked with non-fat 
dry milk or BSA to block any non-specific binding sites of the primary antibody. After blocking, 
membranes are incubated with a specific primary antibody and the appropriate secondary antibody. 
Following incubation, proteins can be detected through chemiluminescence, a method that 
incorporates the ability of the horseradish peroxidase conjugated on the secondary antibody to 
catalyze the oxidation of luminol, resulting in the emission of light. This light signal can then be 
detected on X-ray film which can be analyzed in a densitometer 
97
.  
In the present work, samples were collected and their protein concentration determined as 
described in section 3.2.5. Samples were separated on a 5-20% gradient SDS-PAGE in a Hoefer 
electrophoresis system. The gradient gels were prepared and allowed to polymerize for 45 minutes 
at room temperature. Subsequently, the stacking gel solution was prepared and loaded on the top of 
the resolving gel. A comb was inserted into the stacking gel and left to polymerize for 30 minutes 
at room temperature. Prior to loading, LB 4x was added to the samples (1/4 of the final volume), 
boiled for 10 minutes at 90°C and spun down. 
Samples were gently loaded into the wells as well as a molecular weight marker (Precision 
Plus Protein™ Dual Color Standards, Bio-Rad) and gels were run at 90 mA for approximately 3 
hours. Proteins were then electrophoretically transferred onto nitrocellulose membranes 
(Whatman®) for 18 hours at 200 mA. Membranes were incubated with Ponceau S solution for 5 
minutes and scanned in a GS-800 calibrated imaging densitometer (Bio-Rad), in order to assess 
equal gel loading. Following washing in TSB-T 1x to remove the Ponceau S staining, membranes 
were blocked with 5% BSA in Tris Buffered Saline Tween (TBS-T) 1x for 4 hours. Membranes 
were then washed in TBS-T 1x for 10 minutes, incubated with a specific primary antibody 
(depicted in Table 3) overnight, washed thrice with TBS-T 1x for 10 minutes each, incubated with 
the appropriate secondary antibody for 2 hours and washed thrice with TBS-T 1x for 10 minutes. 
Following the last wash, membranes were incubated with enhanced chemiluminescence (ECL) 
detection kit for 1 minute or with Luminata™ Crescendo Western HRP Substrate (GE Healthcare) 
for 5 minutes, in a dark room. After exposure of the membranes to X-ray films (Kodak), these were 
developed and fixed with the appropriate solutions (Kodak). Films were then scanned in a GS-800 
calibrated imaging densitometer (Bio-Rad) and the results analyzed. 
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3.5. Immunocytochemistry 
Immunocytochemistry is a technique that permits the visualization of the localization of a 
specific protein in animal cells and tissues fixed in paraformaldehyde (PFA) 
96
. 
Initially, samples are prepared by fixing with a fixation agent, which helps to stabilize and 
preserve cells as close to life-like as possible by binding to reactive groups on proteins and lipids in 
the cells and holding them in the same position as if they were in living cells. Then cells are 
permeabilized so that antibodies penetrated inside fixed cells. This is achieved by the addition of 
detergents, which can solubilize membranes without destroying protein-protein interactions. 
Following permeabilization, cells are blocked, incubated with the proper specific antibody and 
appropriated fluorescent secondary antibody and mounted on a microscope slide. Cells are 
mounted in a media with anti-fading and anti-photobleaching properties. Subsequently preparation 
can be visualized through a microscope and the images analyzed 
96
. 
In the present work, cell culture was performed as described in 3.2.4 in 24-well plates 
(Corning) with coverslips. Cells were then washed with PBS 1x and 300 μL of 4% PFA was added 
for 20 minutes. Following fixation, cells were washed trice with PBS 1x and 300 μL of 0.2% 
Triton-X was added for 10 minutes. Cells were then incubated for 2 hours with the specific 
antibodies, as depicted in Table 3, followed by incubation for 1 hour with the appropriate 
fluorescent antibodies (Table 7). Cells were washed thrice with PBS 1x following permeabilization 
with 0.2% Triton-X, between antibody incubation periods and after incubation with the secondary 
antibodies. Samples were then mounted on a microscope slide with VECTASHIELD® Mounting 
Media with DAPI (Vector Laboratories) and visualized using a LSM510-Meta confocal 
microscope (Zeiss) and a 63x/1.4 oil immersion objective. The argon laser lines of 405 nm, 488 
nm, and a 561 nm DPSS laser were used. Profiles were acquired using the Zeiss LSM 510 4.0 
software. 
Table 7 – Secondary antibodies used in immunocytochemistry 
Antibody 
Excitation maximum 
(nm) 
Emission maximum 
(nm) 
Observed 
colour 
Alexa Fluor 594 goat anti-
mouse IgG (Invitrogen) 
590 617 Red 
Alexa Fluor 488 goat anti-
rabbit IgG (Invitrogen) 
495 519 Green 
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Following image acquisition, co-localization analysis was performed to assess whether Aβ 
would affect the co-localization between neurabin-1 and both PP1s. Co-localization is occasionally 
used to estimate the interaction between different molecules, i.e., if different proteins interact with 
each other. However, when two proteins co-localize, it does not imply that these interact with each 
other but it supports a physical interaction in vivo 
103
. 
The co-localization analysis was performed in the Fiji image processing package, using the 
JACoP plugin. This plugin uses several pixel intensity spatial correlation methods to determine 
colocalization between two different colour channels, such as the Manders, the Costes, the Pearson 
or the Li methods. In the work here described, results were obtained using the Manders' method, 
since it is normally the most used when comparing two objects of different amounts (in this case 
two proteins which have different expression levels) 
103,104
. 
Co-localization of PP1α and neurabin-1 was analyzed using 79 and 101 cells for controls and 
cells treated with Aβ1-42, respectively. For the PP1γ and neurabin-1 analysis, 91 and 85 cells were 
analyzed for controls and cells treated with Aβ1-42, respectively. Finally, for the neurabin-2 and 
neurabin-1 analysis, 62 and 59 cells were analyzed for controls and cells treated with Aβ1-42, 
respectively.  
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4. Results & Discussion 
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4.1. Differentiation of the SH-SY5Y cell line 
In order to use a cell line closer to neurons, an experiment design was delineated so as to 
optimize the best media combination for SH-SY5Y differentiation. Initial plating density was of 
1x10
5
 per well and cells were allowed to differentiate for 10 days, with media renewal every 2 
days. Every 2 days, photographs were taken and those cells collected for further WB analysis. 
SH-SY5Y cells are often used in neuroscience due to their ability to differentiate in a more 
mature neuron-like phenotype. SH-SY5Y cells generally have two morphologically distinct types: 
“S” and “N”. The “S”-type is more epithelial-like with no processes, whereas the “N”-type is more 
neuronal-like with pyramidal bodies and long processes. “S”-type cells generally do not 
differentiate and can even begin to replicate indefinitely even when RA, which has growth-
inhibition properties, is added to the media. So, an optimized differentiation media should be able 
to tip the balance in favor of the “N”-type population 98. 
To evaluate whether SH-SY5Y cells were differentiated, we decided to look at important 
characteristics: morphological changes, such as neurite extension, and the expression of neuronal 
markers, such as the increase in β3-tubulin and microtubule-associated protein 2 (MAP2) 98,105. 
Additionally, the presence of “S”-type cells was also evaluated. 
4.1.1. Morphological evaluation 
To evaluate the morphological changes induced by each media, photographs of cells were 
taken, in every type of media, every 2 days, depicted in the following images (Figure 9, Figure 10 
and Figure 11). No photographs were taken of media E at the 4
th
, 6
th
 and 8
th
 day due to a technical 
issue in the camera.  
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Figure 9 – Phase contrast photographs of SH-SY5Y cells grown in media A and B. A-E 
represents control cells at days 2, 4, 6, 8 and 10, in this order; F-J represents differentiated cells grown in 
media A at days 2, 4, 6, 8 and 10, in this order. K-O represents differentiated cells grown in media B at days 
2, 4, 6, 8 and 10, in this order. Black arrows represent extended neurites. Black triangles represent “S” 
population. 
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Figure 10 – Phase contrast photographs of SH-SY5Y cells grown in media C and D. A-E 
represents control cells at days 2, 4, 6, 8 and 10, in this order; F-J represents differentiated cells grown in 
media C at days 2, 4, 6, 8 and 10, in this order. K-O represents differentiated cells grown in media D at days 
2, 4, 6, 8 and 10, in this order. Black arrows represent extended neurites. Black triangles represent “S” 
population.  
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Figure 11 – Phase contrast photographs of SH-SY5Y cells grown in media E. A and B represent 
control cells at day 2 and 10, respectively; C and D represent differentiated cells at day 2 and 10, 
respectively. Black arrows represent extended neurites. 
The following table summarizes the different morphological changes induced by each 
different media. Even though no photos were taken of media E at the 4
th
, 6
th
 and 8
th
 days, the 
morphological analysis was still carried out.  
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Table 8 – SH-SY5Y morphological changes induced by the media 
Media Day Neurite extension Proliferation rate “S” population 
A 
2 +/- + - 
4 + ++ - 
6 +/- ++ + 
8 - ++ + 
10 - ++ + 
B 
2 + + - 
4 + ++ - 
6 +/- ++ +/- 
8 - ++ + 
10 - ++ ++ 
C 
2 +/- - - 
4 + - - 
6 + + +/- 
8 +/- + + 
10 +/- + + 
D 
2 + - - 
4 + - - 
6 + + +/- 
8 +/- + + 
10 +/- + + 
E 
2 ++ - - 
4 ++ -- - 
6 n/a n/a n/a 
8 n/a n/a n/a 
10 n/a n/a n/a 
+, increased; ++, more increased; +/-, neither increased nor decreased; -, decreased; --, more decreased; n/a, 
almost no cell was available for proper evaluation. 
 
From the results summarized in Table 8, it was possible to observe that cells grown in media 
A and B had an increased proliferative rate, with the number of cells increasing rapidly each 2 days 
(Figure 9). Cells grown in media C and D showed a decreased proliferative rate in the initial days, 
however, their number began to increase rapidly from the 6
th
 day onward (Figure 10). As for cells 
grown in media E, they began to die between the 4
th
 and 6
th
 days, with almost no cells left in the 
10
th
 day (Figure 11B). 
Neurite extension was higher in cells grown in media C, D and E than cells grown in media 
A and B. By comparing media C, D and E, it is possible to observe more developed neurites in the 
latter, while C and D did not exhibit significant differences between them. 
The “S” population increased in all media beginning at the 6th day (media E excluded). By 
the 10
th
 day, all cultures were overgrown by this type of population, with almost no “N”-type cell 
left. 
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It is known that RA has growth-inhibition properties 
98
. Thus, when added to the media, SH-
SY5Y cells should choose to differentiate rather than divide. However, cells grown in media with 
high serum concentration (media A and B) preferred to divide. Contrarily, cells grown in media 
with low serum concentration (media E) chose to differentiate, eventually dying between the 4
th
 
and 6
th
 days. This was probably due to RA’s toxic effects and low FBS concentration, as FBS 
provides cells growth factors, hormones, fatty-acids, vitamins and other proteins, necessary for 
their survival 
106
. Controls of media A-D also have shown this fact. Control cells of media A and B 
divided continuously, and in the 8
th
 and 10
th
 days they were so high in number that eventually 
started entering apoptosis, probably due to lack of space, which SH-SY5Y require to proliferate  
98
. 
One common aspect to all types of media was the fact that “S”-type cells began to appear at 
the 6
th
 day and eventually, cultures were overgrown by this type of cells. As can be seen in Figure 9 
and Figure 10 (black triangles), “S”-type cells do not have neurites, tend to grow in clusters and 
have a more epithelial-like phenotype. This aspect has been documented before, with short term 
RA treatment appearing to induce differentiation of the “N”-type population, while longer 
treatments promoted proliferation of the “S”-type population, thus resulting in an unbalanced 
proportion between both populations 
98
. As a result of this observation, it was concluded that the 
differentiating media that would be chosen could only be used on SH-SY5Y cells up to 4 days. 
No significant morphological differences were seen between media C and D. It was 
concluded that either concentration of RA (10 or 20 μM) appeared to have the same results in the 
morphological changes of SH-SY5Y cells. 
Controls of all types of media also have shown an interesting aspect. By observing all 
control conditions, it is possible to observe that by only reducing the serum concentration of media, 
SH-SY5Y cells began to develop more extended neurites. Controls of media A and B (Figure 9, A-
E) showed that cells with higher concentration of serum in the media prefer to divide and 
proliferate, almost exclusively. However cells with lower concentration of serum began to develop 
neurites, as can be seen in Figure 10 (A-E) and Figure 11 (A, B). In the latter this change is more 
prominent, with cells at the 10
th
 day having developed neurites almost as extended as cells grown 
in media C and D. This is probably due to the fact that the media has low levels of FBS, thus 
almost no growth factor 
106
. Since there is almost no growth factor in the media, cells could not 
divide and proliferate but did differentiate. 
Thus, by analyzing this data, it is possible to conclude that media C, D and E induced more 
neuronal-like morphological changes than media A and B. Media C and D had no significant 
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changes between them at the morphological level, and media E lead to cell apoptosis when used for 
more than 4 days. 
4.1.2. Neuronal markers analysis 
Since morphological evaluation of SH-SY5Y cells is not sufficient to conclude whether a 
population is differentiated or not, WB analysis was carried out to detect the levels of two proteins 
commonly used as neuronal markers, β3-tubulin and MAP2 98. With the results obtained from the 
morphological evaluation, WB analysis was performed for media C, D and E. The following 
images summarize the results obtained. 
 
Figure 12 – Protein analysis of SH-SY5Y cells grown in media C and D. A. Western blot analysis 
of control SH-SY5Y cells and cells differentiated for 10 days using media C and D. B. Comparison of MAP2 
between control cells and cells grown in media C and D. C. Comparison of β3-tubulin between control cells 
and cells grown in media C and D. Data was normalized to control levels for better comparison. All data was 
normalized to Ponceau S levels prior to analysis. C, control; mC, media C; mD, media D. 
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Figure 13 – Protein analysis of SH-SY5Y cells grown in media E. A. Western blot analysis of 
control SH-SY5Y cells and cells differentiated for 10 days using media E. B. Comparison of MAP2 between 
control and cells grown in media E. C. Comparison of β3-tubulin between control and cells grown in media 
E. Data was normalized to control levels for better comparison. All data was normalized to Ponceau S levels 
prior to analysis. 
By analyzing Figure 12 it is possible to conclude the same as previous seen in the 
morphological analysis. Cells grown in media C and D did not exhibit many differences between 
them at the protein expression levels. By comparing both media with the controls, it is possible to 
observe that all three media exhibited roughly the same protein expression levels. 
Cells grown in media E showed an increased expression of both MAP2 and β3-tubulin 
compared to the controls in the initial days (Figure 13). In the following days (6
th
 and 8
th
), both 
MAP2 and β3-tubulin expression levels in control cells and cells grown in media E were similar, 
with control cells in the 10
th
 day having a higher expression of both markers. Since cells grown in 
media E began to die from the 4
th
 day onwards and control cells began to exhibit extended neurites 
when cultured for more than 4 days, this likely explains why the neuronal markers expression was 
similar between both control and cells grown in media E after the 4
th
 day. 
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Concluding, cells grown in media C and D did not exhibit many differences compared to the 
controls, while media E exhibited more neuronal markers expression in the initial days (2
nd
 and 4
th
). 
Thus, and by analyzing both the morphological changes and the protein markers expression, 
it was concluded that media E would be the most appropriate media for inducing SH-SY5Y 
differentiation. Additionally, since cells began to die from the 4
th
 day onward and the Aβ treatment 
requires 24 hours of culture, it was decided that cells would be cultured in media E for 2 days. 
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4.2. Aβ effect on neurabins expression 
Aβ is a neurotoxic peptide which can lead to spine and synapse degeneration. Even when Aβ 
is applied extracellularly to SH-SY5Y cells, it is taken up by these cells, causing mitochondria 
damage 
89
 and neurite damage 
107
, events that ultimately lead to spine degeneration. 
Since neurabin-1 and neurabin-2 are highly concentrated in the spine, especially in the PSD 
29,73
, and are important to spine morphogenesis and spine dynamics 
27,38,52
, their expression could be 
decreased in situations where this toxic peptide is present. 
To test so, rat primary hippocampal cultures were cultured as described in section 3.2.4 and 
WB analysis was performed to assess both neurabin-1 and neurabin-2 expression (Figure 14). 
Additionally, the same analysis was performed in SH-SY5Y cells grown in media E to assess 
whether the SH-SY5Y culture behaved as the primary culture (Figure 15), thus allowing one to 
conclude whether this cell type would be suitable for neurabin-1 and neurabin-2 analysis. 
 
Figure 14 – Neurabin-1 and neurabin-2 expression in rat primary hippocampal cultures treated 
with Aβ1-42. A. Western blot of rat hippocampus lysates treated with different concentration of Aβ1-42. B. 
Comparison of neurabin-1 expression in cells with different types of Aβ1-42 treatment. C. Comparison of 
neurabin-2 expression in cells with different types of Aβ1-42 treatment. C, 2 and 10 represents control cells 
and cells treated with 2 and 10 μM of Aβ1-42, respectively. All data was normalized to Ponceau S levels prior 
to analysis. Horizontal bars on B and C represent standard deviation, n = 3 (1-way ANOVA). 
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By analyzing Figure 14B it is possible to identify a tendency to decrease in neurabin-1 
expression, perhaps due to the loss of synapses and dendritic spines typically caused by Aβ 
exposure, as seen in AD patients. 
The results obtained with neurabin-2 (Figure 14C) point to a decrease in its expression in 
cells treated with Aβ1-42 at high concentrations (10 μM). Several studies used this protein as a 
marker for spine density in transgenic mice with enhanced production of Aβ, and concluded that 
this protein is greatly reduced 
108–110
. Thus, the tendency to decrease, seen here, is in agreement 
with the results obtained by other groups, which helps to speculate that the rat primary 
hippocampal cultures treated with 10 μM of Aβ1-42 may have few number of spines compared to the 
controls. However, to properly conclude this, more samples need to be analyzed. 
 
Figure 15 – Neurabin-1 and neurabin-2 expression in SH-SY5Y cells treated with Aβ1-42. A. 
WB analysis of SH-SY5Y lysates treated with different concentration of Aβ1-42. B. Comparison of 
neurabin-1 expression in cells with different types of Aβ1-42 treatment. C. Comparison of neurabin-2 
expression in cells with different types of Aβ1-42 treatment. C, 2 and 10 represents control cells and cells 
treated with 2 and 10 μM of Aβ1-42, respectively. All data was normalized to Ponceau S levels prior to 
analysis. Horizontal bars on B and C represent standard deviation, n = 4, *p < 0.05 (1-way ANOVA). 
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The results obtained with the SH-SY5Y cells showed a slight decrease in the expression of 
both neurabins (p < 0.05), in agreement with the tendency to decrease seen with the primary 
cultures previously tested. This decrease could be due to the synaptic dysfunction caused by Aβ 
and consequently, dendritic spine degeneration 
89
. 
The results here obtained with both primary cultures and SH-SY5Y cells suggest that in AD, 
these proteins’ expression levels may be decreased, which could lead to a dysregulation of the actin 
dynamics of dendritic spines. This dysregulation can ultimately lead to dendritic spine and synaptic 
loss, leading to neuronal death and the clinically changes seen in AD 
89,95
. 
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4.3. Aβ effect on the neurabins/PP1 complex 
Both neurabin-1 and neurabin-2 can interact with PP1 in order to regulate several aspects of 
neuronal morphology and synaptic plasticity 
39,40,64,67. Since cells treated with Aβ1-42 are known to 
undergo both morphological and synaptic changes (dendritic spine degeneration, increase of LTD, 
decrease of LTP and neuronal death) 
89
, we tested whether Aβ1-42 interferes with the interaction 
between neurabin-1/2 and PP1. 
To do so, we performed a Co-IP with both PP1α and PP1γ and, through WB, tested the 
interactions between these PP1 and neurabin-1/2. The following images (Figure 16 and Figure 17) 
represent the results obtained. 
 
Figure 16 – Co-immunoprecipitation of PP1α binding proteins in SH-SY5Y. Western blot was 
performed using anti-PP1α to ensure that PP1α was immunoprecipitated, and anti-neurabin-1 and anti-
neurabin-2 antibodies to test their interaction with PP1α. C, controls; 2 and 10, treatment with 2 and 10 μM 
Aβ1-42, respectively; IpC, immunopreciptation controls. 
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Figure 17 – Co-immunoprecipitation of PP1γ binding proteins in SH-SY5Y. Western blot was 
performed using anti-PP1γ to ensure that PP1γ was immunoprecipitated, and anti-neurabin-1 and anti-
neurabin-2 antibodies to test their interaction with PP1γ. C, controls; 2 and 10, treatment with 2 and 10 μM 
Aβ1-42, respectively; IpC, immunoprecipitation controls. 
The results here obtained point to a change in the interaction between neurabin-1 and both 
PP1α and PP1γ, as one of the bands representing neurabin-1 (top one) failed to appear in cells 
treated with Aβ1-42. 
Several articles pointed to the existence of several bands when detecting neurabin-1 through 
WB, suggesting that the two lower bands (two almost united bands, can be distinguished in Figure 
14A) could be proteolytic products of neurabin-1 
24,37,46,48
. If this assumption is correct, then 
perhaps Aβ1-42 at high concentrations could interfere with full-length neurabin-1, inducing a 
conformational change that “hides” the PP1 binding motif, thus preventing its binding. 
Aβ1-42 could also induce physiological signals that increase full-length neurabin-1 interaction 
with another protein, thus displacing PP1 from its binding motif. In fact, it has been shown that 
cytosolic neurabin-1 (without its actin-binding domain) displays a decreased PP1 binding and 
recruits other proteins to the PDZ domain, such as p70S6K 
27
, so a similar mechanism could also be 
happening here when Aβ is present in the cells. 
Additionally, Aβ1-42 could also increase the activity of several kinases which, in turn, 
phosphorylate full-length neurabin-1, thus reducing its affinity for PP1. It is known that the activity 
of several protein kinases and protein phosphatases in the brains of AD patients is altered. ERK2 
and Cdk5 in particular, are known to be increased 
111
, while PKA, the only reported kinase able to 
reduce neurabin-1 affinity for PP1 
27,46
, is decreased 
111
. Thus, it is unlikely that PKA could be the 
one causing the effects seen on the neurabin-1/PP1 complex. As for ERK2 and Cdk5, none of these 
kinases was reported as being able to phosphorylate neurabin-1 in a way that reduces its affinity for 
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PP1 
28,74
. Using the Group-based Prediction System 3.0 (GPS 3.0) 
112
, it was found that neurabin-1 
has several predicted phosphorylation sites by several kinases which have their activity increased in 
AD patients. However, so far, these predicted phosphorylation sites were not tested in vitro/in vivo. 
Furthermore, it is known that both PP1 expression 
111,113
 and activity 
114
 is decreased when 
Aβ is added to the cells. Thus, these disruptions could be due to the cumulative decrease of both 
PP1s and neurabin-1 expression in cells treated with Aβ, although we believe that this is unlikely 
since the decrease of both PP1s and neurabin-1 is not high enough to completely hinder the 
interaction between them. 
However, as of today, none of the bands representing neurabin-1 was individually analyzed. 
Thus, it is impossible to conclude whether the above assumptions could be correct. 
As for neurabin-2, its interaction with both PP1α and PP1γ does not seem to be affected by 
treatment with both 2 and 10 μM of Aβ1-42, since no significant change was seen in neurabin-2’s 
expression. 
Why does the neurabin-1/PP1 complex seem to be affected while the neurabin-2/PP1 
complex is not? Even though it has been suggested that these two proteins (neurabin-1 and 
neurabin-2) are regulators of each other in neurons, they can also interact with different proteins 
and can be phosphorylated by different kinases. Thus, this difference in the interacting partners 
could explain why Aβ affects each complex in a different manner. 
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4.4. Immunocytochemistry of SH-SY5Y cells treated with Aβ1-42 
In order to visualize in vivo whether the neurabin-1/PP1 complex was being disrupted by the 
addition of Aβ, we decided to perform an immunocytochemistry and determine the co-localization 
of neurabin-1 and both PP1α and PP1γ. These experimental procedures also permitted 
characterizing the cellular distribution of both neurabins. 
The following images (Figure 18, Figure 19 and Figure 20) represent the results obtained. 
 
Figure 18 – PP1α and neurabin-1 localization in SH-SY5Y cells. PP1α appears as green, neurabin-
1 as red. Blue represents the nucleus of the cells stained with DAPI. ROI represents the area within the white 
square on merge. White arrow points to an area where both proteins co-localize. A. Control cells. B. SH-
SY5Y cells treated with 10 μM Aβ1-42. C. Co-localization analysis. Results are represented as the mean 
percentage of all cells analyzed for each condition (controls, n = 79; cells treated with Aβ, n = 101). 
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Figure 19 – PP1γ and neurabin-1 localization in SH-SY5Y cells. PP1γ appears as green, neurabin-1 
as red. Blue represents the nucleus of the cells stained with DAPI. ROI represents the area within the white 
square on merge. White arrow points to an area where both proteins co-localize. A. Control cells. B. SH-
SY5Y cells treated with 10 μM Aβ1-42. C. Co-localization analysis. Results are represented as the mean 
percentage of all cells analyzed for each condition (controls, n = 91; cells treated with Aβ, n = 85). 
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Figure 20 – Neurabin-2 and neurabin-1 localization in SH-SY5Y cells. Neurabin-2 appears as 
green, neurabin-1 as red. Blue represents the nucleus of the cells stained with DAPI. ROI represents the area 
within the white square on merge. White arrow points to an area where both proteins co-localize. A. Control 
cells. B. SH-SY5Y cells treated with 10 μM Aβ1-42. C. Co-localization analysis. Results are represented as 
the mean percentage of all cells analyzed for each condition (controls, n = 62; cells treated with Aβ, n = 59). 
By analyzing the above figures (Figure 18, Figure 19 and Figure 20) it is possible to observe 
that neurabin-1 (marked as red) is highly concentrated in the neurites, where the intensity of the 
signal was more intense. It also appears to be highly concentrated in the area surrounding the 
cytoplasm and  within some regions in the cells, perhaps the cell membrane and the actin 
cytoskeleton, respectively, since neurabin-1 is known to interact with several proteins present in the 
cell membrane 
36,50
 and with F-actin 
24,27
. Neurabin-2, as neurabin-1, can be found in the neurites, 
perhaps bound to F-actin. However, it seems to be more distributed within the cytoplasm than 
neurabin-1. The cellular distribution of both neurabin-1 and neurabin-2 does not seem to be 
affected by the treatment with Aβ1-42. 
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In neurons, PP1α is mostly found within dendritic spines and also found in the cytoplasm 
and in the nucleus, while PP1γ is highly concentrated in dendritic spines and presynaptic terminals 
18
. In the work here performed with SH-SY5Y cells, PP1α (marked as green on Figure 18) was 
found to be more expressed in the nucleus and in the cytoplasm, with little expression in the 
neurites. On the other hand, PP1γ (marked as green on Figure 19) was found to be more expressed 
in the neurites than PP1α, but could also be found in the nucleus and cytoplasm. 
The co-localization analysis did not reveal any differences between control cells and cells 
treated with Aβ1-42. The main aims of these experimental procedures were to assess neurabin-1 and 
PP1 co-localization in the presence of Aβ1-42; and to observe whether neurabin-1 would be affected 
by Aβ1-42 in terms of cellular localization. With the results here reported, we could not observe any 
differences between the co-localization of neurabin-1 and both PP1s and we did not see any major 
difference in the localization of neurabin-1. The results obtained with neurabin-2 also did not 
reveal any differences between control cells and cells treated with Aβ1-42. 
Fluorescence microscopy is a reliable technique to determine if two proteins can be found in 
the same cellular compartments and, when they co-localize, this supports a physical interaction in 
vivo. The resolution of a microscope is not sufficient to identify the physical interaction of two 
molecules through a comparison of their distributions in fluorescence images. Such studies require 
higher resolution techniques such as fluorescence resonance energy transfer or electron 
microscopy. Additionally, co-localization analysis can be influenced by background, i.e., low 
signal levels in the image derived from autofluorescence and nonspecific labeling 
103
. This 
background can be eliminated in the acquisition process. Furthermore, the JACoP plugin permits 
the setting of a threshold to determine what we believe to be “true” signal, thus eliminating these 
non-specific signals when analyzing the images. Thus, arising from the fact that fluorescence 
microscopy is not the best approach to quantify the physical interaction between two proteins, and 
the co-localization analysis done afterwards can be prone to subjective errors, it is possible to 
explain why no differences were seen in the co-localization of neurabin-1 and both PP1s, i.e., 
differences between their interactions. 
Nevertheless, the experimental procedure here performed was a preliminary study to assess 
the cellular distribution of neurabin-1 and neurabin-2 in SH-SY5Y cells, and further studies using 
higher resolution techniques are required in order to properly quantify the physical interaction 
between neurabin-1 and both PP1s, when Aβ is added to the cells. 
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5. Conclusion 
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This thesis aimed to evaluate whether Aβ could affect neurabin-1 and neurabin-2 expression, 
and disrupt or affect the neurabins/PP1 complex, which is important for the regulation of synaptic 
transmission, hippocampal plasticity and maintenance of dendritic spine morphology. These 
functions are known to be impaired in AD patients, therefore, studying all the molecular targets 
that could be affected by the overproduction of Aβ, particularly those known to be important in 
proper synaptic transmission, plasticity and dendritic spine morphology could help us to have a 
better understanding of the changes that occur in AD. 
The experiments performed in this work with rat primary hippocampal cultures pointed to a 
slight decrease in both neurabin-1 and neurabin-2 expression when these cells were treated with 
Aβ1-42 at a concentration of 10 μM. Additionally, the experiments performed with differentiated 
SH-SY5Y cells showed a significant decrease in both neurabins expression when treated with Aβ1-
42. These results suggest that neurabins expression in AD patients is decreased, perhaps due to the 
loss of synapses and dendrites (the locus of the majority of both neurabins localization) or due to 
the neuronal death that accompanies these latter changes. Whether neurabin-1 and neurabin-2 
decreased expression is the result of the Aβ effects on the neurabins themselves or the result of the 
neuronal death triggered by Aβ could not be assessed at this point. 
Our Co-IP results showed that the neurabin-1/PP1 complex seems to be affected when Aβ1-42 
is added to the media of the cells at a concentration of 10 μM, while the neurabin-2/PP1 complex 
did not seem to be affected by any of the Aβ1-42 concentration. Based on these findings, we 
hypothesized three different models, which could link the disruptive effects of Aβ on the 
neurabin/PP1 complex to the changes seen in AD (Figure 21). However, none of these hypotheses 
could be confirmed at this point. 
The immunocytochemistry here performed and the co-localization analysis did not 
demonstrate any differences between the co-localization of neurabin-1 and both PP1α and PP1γ 
when Aβ1-42 was added to the cells. Moreover, Aβ1-42 did not seem to affect the cellular distribution 
of neurabin-1 and neurabin-2, since no major differences were seen when compared to controls. 
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Figure 21 – Proposed models for the effect of Aβ on the neurabin/PP1 complex. The Aβ effects 
on the neurabin/PP1 complex would lead to changes in the spine dynamics which would eventually lead to 
synaptic loss and ultimately to neuronal death. A. Neurabin/PP1 complex under normal physiological 
conditions with PP1 bound to the PP1-binding domain of neurabin. B. Aβ could induce a conformational 
change in neurabin which would hide the PP1-binding domain. C. Aβ could increase neurabin’s affinity for 
another protein (which binds to its PDZ domain, for example), displacing PP1 from its binding site. D. Aβ 
could increase the activity of a protein kinase, which would phosphorylate neurabin, displacing PP1 from its 
binding site. 
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Future Perspectives 
In future works with neurabin-1, it would be of high importance to individually study what 
each band found in the WB analysis represents. This study would elucidate and help us understand 
the results obtained with our Co-IP. To do so, we could run a SDS-PAGE, cut the area where 
neurabin-1 can be found and submit it to mass-spectrometry analysis, which would identify the 
sequence of the protein present in each of the bands 
115
. 
Additionally, it would be important to increase the number of experiments carried out with 
both rat primary hippocampal cultures and SH-SY5Y cells. This would increase the reliability of 
the results obtained with both neurabin-1 and neurabin-2 expression when cells were treated with 
Aβ. Moreover, it would be important to repeat the Co-IP in rat primary hippocampal cultures in 
order to reproduce the results obtained in SH-SY5Y cells. 
It would also be interesting to increase the number of days that cells are treated with Aβ1-42, 
as it would allows one to understand if the decrease seen with both neurabin-1 and neurabin-2 
expression is proportional to the amount of time cells are exposed to Aβ. 
Finally, it would be important to use microscopic techniques with higher resolution to 
compare the co-localization of neurabin-1 and both PP1s, such as electron microscopy, 
fluorescence resonance energy transfer 
103
 or proximity ligation assay 
116
. 
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Cell Culture Solutions 
 PBS (1x) 
For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
 8 mM Sodium Phosphate 
 2 mM Potassium Phosphate 
 140 mM Sodium Chloride 
 10 mM Potassium Chloride 
Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
 10% FBS MEM:F12 (1:1) 
 4.805 g MEM 
 5.315 g F12 
 1.5 g NaHCO3 
 0.055 g Sodium Pyruvate 
 10 mL Streptomycin/Penicillin/Amphotericin solution 
 100 mL 10% FBS 
 2.5 mL L-glutamine (200 mM stock solution) 
Dissolve in deionised H2O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 mL with 
deionised H2O. 
For other combinations of FBS, replace 100 mL FBS with 30 mL (3% FBS MEM:F12), 10 
mL (1% FBS MEM:F12) or remove FBS (serum-free MEM:F12). 
 
 10 mg/mL Poly-D-lysine stock (100x) 
To a final volume of 10 mL, dissolve in deionesed H2O 100 mg of poly-D-lysine (Sigma-
Aldrich). 
 
 Borate buffer 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid (Sigma-Aldrich). 
Adjust pH to 8.2, sterilize by filtering through a 0.2 μM filter, and store at 4°C. 
 
 Poly-D-lysine solution 
To a final volume of 100 mL, dilute 1 mL of the 10 mg/mL poly-D-lysine stock solution in 
borate buffer. 
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 Hank’s Balanced Salt Solution (HBSS) 
This salt solution is prepared with deionised H2O. Final composition: 
 137 mM NaCl 
 5.36 mM KCl 
 0.44 mM KH2PO4 
 0.34 mM Na2HPO42H2O 
 4.16 mM NaHCO3 
 5 mM Glucose 
 1 mM Sodium Pyruvate 
 10 mM HEPES 
Adjust pH to 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
 Complete Neurobasal medium 
This serum-free medium (Neurobasal; Gibco) is supplemented with: 
 2% B27 supplement 
 0.5 mM L-glutamine 
 25 μM L-glutamate 
 60 μg/mL Gentamicine 
 0.001% Phenol Red 
Adjust pH to 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
 
Western Blot Solutions 
 LGB (lower gel buffer) (4x) 
To 900 mL of deionised H2O add: 
 181.65 g of Tris 
 4 g of SDS 
Mix until the solutes have dissolved. Adjust pH to 8.9 and adjust the volume to 1 L with 
deionised H2O. 
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 UGB (Upper gel buffer) (4x) 
To 900 mL of deionised H2O add: 
 75.69 g of Tris 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L with 
deionised H2O. 
 
 10% APS (ammonium persulfate) 
In 10 mL of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
 
 10% SDS (sodium dodecilsulfate) 
In 10 mL of deionised H2O dissolve 1 g of SDS. 
 
 Loading Gel Buffer (4x) 
 2.5 mL 1M Tris solution (pH 6.8) 2.5 mL (250 mM) 
 0.8 g SDS (8%) 
 4 mL Glicerol (40%) 
 2 mL β-mercaptoethanol (2%) 
 1 mg Bromofenol blue (0.01%) 
Adjust the volume to 10 mL with deionised H2O. Store in darkness at room temperature. 
 
 1 M Tris (pH 6.8) solution 
To 150 mL of deionised H2O add: 
 30.3 g Tris base 
Adjust the pH to 6.8 and adjust the final volume to 250 mL with deionised H2O. 
 
 10x Running Buffer 
 30.3 g Tris (250 mM) 
 144.2 g Glycine (2.5 M) 
 10 g SDS (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
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 Stacking and resolving gel 
Type of Gel Stacking Resolving 
Polyacrylamide percentage 3.5 % 5 % 20 % 
H2O 13.2 mL 17.4 mL 2.2 mL 
Acrylamide stock mixture 2.4 mL 5 mL 20 mL 
UGB (5x) 4 mL n/a n/a 
LGB (4x) n/a 7.5 mL 7.5 mL 
10% SDS 200 μL n/a n/a 
10% APS 200 μL 150 μL 150 μL 
TEMED 20 μL 15 μL 15 μL 
 
 Transfer Buffer (1x) 
 3.03 g Tris (25 mM) 
 14.41 g Glycine (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 
mL with deionised H2O. Just prior to use add 200 mL of methanol (20%). 
 
 10x TBS (Tris buffered saline) 
 12.11 g Tris (10 mM) 
 87.66 g NaCl (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
 
 10x TBST (TBS+Tween) 
 12.11 g Tris (10 mM) 
 87.66 g NaCl (150 mM) 
 10 mL Tween-20 (0.01%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
 
 Membranes Stripping Solution (500 mL) 
 3.76 g Tris-HCl (62.5 mM) 
 10 g SDS (2%) 
 3.5 mL β-mercaptoethanol (100 mM) 
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the β-
mercaptoethanol and adjust volume to 500 mL. 
 
 Blocking solution 
To 20 mL of TBS 1x add 1 g of Bovine Serum Albumine (BSA). 
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Immunofluorescence Solutions 
 
 Blocking solution 
To 10 mL of PBS 1x add 0.3 g of Bovine Serum Albumine (BSA). 
 
 4% Paraformaldehyde 
For a final volume of 100 mL, add 4 g of paraformaldehyde to 25 mL deionised H2O. 
Dissolve by heating the mixture at 58°C while stirring. Add 1-2 drops of 1 M NaOH to 
clarify the solution and filter through a 0.2 μM filter. Add 50 mL of PBS 2x and adjust the 
volume to 100 mL with deionised H2O. 
